Noncontrast Chest Computed Tomographic Imaging of Obesity and the Metabolic Syndrome

Citation for published version:

Digital Object Identifier (DOI):
10.1097/RTI.0000000000000391

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published in:
Journal of Thoracic Imaging

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Non-Contrast Chest Computed Tomographic Imaging of the Metabolic Syndrome (MetS): Part I Cardiovascular Findings
--Manuscript Draft--

<table>
<thead>
<tr>
<th>Manuscript Number:</th>
<th>JTI-18-133R1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Title:</td>
<td>Non-Contrast Chest Computed Tomographic Imaging of the Metabolic Syndrome (MetS): Part I Cardiovascular Findings</td>
</tr>
<tr>
<td>Article Type:</td>
<td>Review Article (Invited)</td>
</tr>
<tr>
<td>Section/Category:</td>
<td>Cardiovascular (cardiac/aortic diseases)</td>
</tr>
<tr>
<td>Keywords:</td>
<td>Metabolic Syndrome, Computed Tomography, Coronary artery Calcification</td>
</tr>
</tbody>
</table>
| Corresponding Author:      | Mark L. Schiebler, M.D.  
University of Wisconsin-Madison  
Madison, Wisconsin UNITED STATES |
| Corresponding Author's Institution: | University of Wisconsin-Madison |
| Order of Authors:          | Christopher L. Schlett, M.D., M.P.H.  
Johanna Nattenmüller, MD  
Nanae Tsuchiya, M.D., PhD  
Jens Vogel-Claussen, MD  
Hans-Ulrich Kauczor, MD  
David L. Levin, M.D., PhD  
Hiroto Hatabu, M.D., PhD  
Jose Raul Estépar, MD  
Ming-Ting Wu, MD  
Edwin J.R. van Beek, M.D., PhD  
Mark L. Schiebler, M.D. |
| Manuscript Region of Origin: | UNITED STATES |
| Abstract:                  | There are physiological consequences of overeating that can lead to increased morbidity and mortality. Purpose of this review article is to acquaint the reader with the current state of the art in the non-cardiac gated, non-contrast chest Computed Tomographic (NCCT) imaging biomarkers of the metabolic syndrome (MetS) and their prognostic significance found in the lower neck and chest. NCCT Imaging biomarkers, associated with MetS in the chest include premature coronary artery calcification, acceleration of large vessel arterial and valvular calcifications associated with atherosclerosis, and pulmonary arterial enlargement from pulmonary hypertension associated with sleep apnea. These easily identified imaging biomarkers have prognostic implications for Major Adverse Cardiac Events (MACE). These NCCT chest-imaging biomarkers are likely targets for artificial intelligence algorithms to harvest for longitudinal assessment of their individual and multifactorial contributions to chronic disease, MACE and mortality. Early recognition and treatment of these common disorders may help improve patient outcomes and quality of life while decreasing medical costs. |
Joseph Schoepf, M.D.
Editor in Chief, Journal of Thoracic Imaging

Re: R1 JT1-18-133

Title: NON-CONTRAST CHEST COMPUTED TOMOGRAPHY OF OBESITY AND THE METABOLIC SYNDROME (METS): PART I CARDIOVASCULAR FINDINGS

Dear Dr. Schoepf,

Thank you for the opportunity to participate in the JTI Special Issue for January 2019.

We have made the suggested changes in the manuscript according to your and the reviewer comments. Each comment is listed in order below. Our responses and changes in the manuscript put into are highlighted in yellow. We have changed the title slightly so that Part I and Part 2 have the same wording. Specifically the two words “Obesity and” have been added. We also added a supplemental figure from Raul Estepar’s group on segmenting the left ventricle on non contrast non gated chest CT exams.

Reviewer #1:

1. Please name NCCT as Non contrast chest computed tomography in the abbreviation page.

   Done

   NCCT Non contrast Computed Tomography

2. In Heart and Valves Section - "...While all cardiac structures are affected by cardiac motion, there is increasing evidence that, with newer hardware low-dose NG-NCCT cardiac motion is less of a problem for calcification and myocardial scar assessment/quantification..) Please use the relevant references to support the mentioned evidence. Equally importantly please ensure that motion artefact especially in the assessment of small anatomical structures as coronary arteries, coronary artery calcifications can be influenced by heart rate dependent motion artefact and also the chosen CT protocol.

   Good point here. We have added the following.
While all cardiac structures are affected by cardiac motion, there is increasing evidence that, with newer hardware, and faster gantry rotation times, low-dose NG-NCT cardiac motion is less of a problem for calcification and myocardial scar assessment/quantification (Figures 1-4).(12-15)

3. In Coronary Artery Calcification section - It is proper to use the reference of Wu et al about the correlation between gated and non gated CT protocol based coronary calcium assessment. The authors mentioned an explanation that the quoted good correlation is due to thinner slice reconstruction which is misleading. The referenced article from 2008 used 16 slice MDCT with a mean heart rate of around 61beats/min. Thus it is important to emphasize in the presented review the importance of potential heart rate dependent motion artefact that can limit potentially significantly the accurate quantification of calcium score using non gated CT protocols.

We have added the following:

In a study by Wu et al (28) on 483 patients showed excellent correlation of Agatston CAC scores between a dedicated cardiac gated non-contrast CT for calcium scoring (16 slice multidetector, 3.0 mm slice thickness) and a low dose NG-NCT ( 16 slice multidetector, 0.75mm slice thickness )performed for lung cancer screening (Figure 1). In their cohort of NG-NCT patients the average heart was 61 beats per minute. They did not assess the importance of potential heart rate dependent motion artifact that may limit the accurate quantification of calcium score using non gated CT protocols.(28)

4. It would be beneficial to have a section of Radiation since the presented evidence may support potential CT screening for patients with Metabolic Syndrome.

We have added the following:

Radiation dose and safety using NG-NCT for the diagnosis of MetS

We are not proposing to use NCCT for the diagnosis of MetS or obesity. From studies performed for other indications, the imaging physician can also make inferences about the metabolic milieu of that subject based on the multiple imaging findings discussed in this review. For the most, part low dose chest CT protocols are very low contributors to the medical radiation any patient receives over the course of their lifetime.(78) Each scan delivers between 0.5 and 5 mSv depending on the patient size, use of dose lowering reconstruction methods and automatic exposure control (limit mAs).(79)

EDITOR COMMENTS:

Editor in Chief comments: Add these references.
These referencences have been added to the manuscript.


Joseph Schoepf, M.D.
Editor in Chief, Journal of Thoracic Imaging

Re: R1 JT1-18-133
Title: NON-CONTRAST CHEST COMPUTED TOMOGRAPHY OF OBESITY AND THE METABOLIC SYNDROME (METS): PART I CARDIOVASCULAR FINDINGS

Dear Dr. Schoepf,

Thank you for the opportunity to participate in the JTI Special Issue for January 2019.

We have made the suggested changes in the manuscript according to your and the reviewer comments. Each comment is listed in order below. Our responses and changes in the manuscript put into are highlighted in yellow. We have changed the title slightly so that Part I and Part 2 have the same wording. Specifically the two words “Obesity and” have been added. We also added a supplemental figure from Raul Estepar’s group on segmenting the left ventricle on non contrast non gated chest CT exams.

Reviewer #1:

1. Please name NCCT as Non contrast chest computed tomography in the abbreviation page.

   Done
   
   NCCT Non contrast Computed Tomography

2. In Heart and Valves Section - "...While all cardiac structures are affected by cardiac motion, there is increasing evidence that, with newer hardware low-dose NG-NCCT cardiac motion is less of a problem for calcification and myocardial scar assessment/quantification..) Please use the relevant references to support the mentioned evidence. Equally importantly please ensure that motion artefact especially in the assessment of small anatomical structures as coronary arteries, coronary artery calcifications can be influenced by heart rate dependent motion artefact and also the chosen CT protocol.

   Good point here. We have added the following.
While all cardiac structures are affected by cardiac motion, there is increasing evidence that, with newer hardware, and faster gantry rotation times, low-dose NG-NCCT cardiac motion is less of a problem for calcification and myocardial scar assessment/quantification (Figures 1-4).(12-15)

3. In Coronary Artery Calcification section - It is proper to use the reference of Wu et al about the correlation between gated and non gated CT protocol based coronary calcium assessment. The authors mentioned an explanation that the quoted good correlation is due to thinner slice reconstruction which is misleading. The referenced article from 2008 used 16 slice MDCT with a mean heart rate of around 61beats/min. Thus it is important to emphasize in the presented review the importance of potential heart rate dependent motion artefact that can limit potentially significantly the accurate quantification of calcium score using non gated CT protocols.

We have added the following:

In a study by Wu et al (28) on 483 patients showed excellent correlation of Agatston CAC scores between a dedicated cardiac gated non-contrast CT for calcium scoring (16 slice multidetector, 3.0 mm slice thickness) and a low dose NG-NCCT ( 16 slice multidetector, 0.75mm slice thickness )performed for lung cancer screening (Figure 1). In their cohort of NG-NCCT patients the average heart was 61 beats per minute. They did not assess the importance of potential heart rate dependent motion artifact that may limit the accurate quantification of calcium score using non gated CT protocols.(28)

4. It would be beneficial to have a section of Radiation since the presented evidence may support potential CT screening for patients with Metabolic Syndrome.

We have added the following:

Radiation dose and safety using NG-NCCT for the diagnosis of MetS

We are not proposing to use NCCT for the diagnosis of MetS or obesity. From studies performed for other indications, the imaging physician can also make inferences about the metabolic milieu of that subject based on the multiple imaging findings discussed in this review. For the most, part low dose chest CT protocols are very low contributors to the medical radiation any patient receives over the course of their lifetime.(78) Each scan delivers between 0.5 and 5 mSv depending on the patient size, use of dose lowering reconstruction methods and automatic exposure control (limit mAs).(79)
These references have been added to the manuscript.


Title: Non-Contrast Chest Computed Tomographic Imaging of Obesity and the Metabolic Syndrome (MetS): Part I Cardiovascular Findings

Authors: Christopher L. Schlett, MD MPH (1,2); Johanna Nattenmüller, MD (1,2); Nanae Tsuchiya, MD PhD (3,4); Jens Vogel-Clausen, MD (5); Hans-Ulrich Kauczor, MD (1,2); David Levin, MD PhD(6); Hiroto Hatabu, MD PhD FACR (7); Jose Raul Estépar, MD (8); Ming-Ting Wu, MD (9,10); Edwin J.R. van Beek, MD PhD (11) and Mark L. Schiebler MD (4)

Representing the International Workshop for Pulmonary Functional Imaging (IWPFI)

Author Affiliations:
1. Department of Diagnostic and Interventional Radiology, University Hospital of Heidelberg, Heidelberg, Germany.
2. Translational Lung Research Center (TLRC) Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
3. Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, Okinawa 903-0215, Japan
4. Department of Radiology, University of Wisconsin-Madison, Madison, WI, USA
5. Department of Radiology, University Hospital Hannover, Germany
6. Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
7. Department of Radiology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
8. Department of Pulmonary Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
9. Department of Radiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
10. Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan
11. Edinburgh Imaging, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK

Corresponding Author:
Mark L. Schiebler, M.D.
Professor of Radiology
UW-Madison School of Medicine and Public Health
600 Highland Avenue
Madison, Wisconsin
Telephone: 608-263-1229
Fax:
Email: mschiebler@uwhealth.org
Title: Non-Contrast Chest Computed Tomographic Imaging of Obesity and the Metabolic Syndrome (MetS): Part I Cardiovascular Findings

Authors: Christopher L. Schlett, MD MPH (1,2); Johanna Nattenmüller, MD (1,2); Nanae Tsuchiya, MD PhD (3,4); Jens Vogel-Clausen, MD (5); Hans-Ulrich Kauczor, MD (1,2); David Levin, MD PhD(6); Hiroto Hatabu, MD PhD FCR (7); Jose Raul Estépar, MD (8); Ming-Ting Wu, MD (9,10); Edwin J.R. van Beek, MD PhD (11) and Mark L. Schiebler MD (4)

Representing the International Workshop for Pulmonary Functional Imaging (IWPFI)

Author Affiliations:

1. Department of Diagnostic and Interventional Radiology, University Hospital of Heidelberg, Heidelberg, Germany.
2. Translational Lung Research Center (TLRC) Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
3. Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, Okinawa 903-0215, Japan
4. Department of Radiology, University of Wisconsin-Madison, Madison, WI, USA
5. Department of Radiology, University Hospital Hannover, Germany
6. Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
7. Department of Radiology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
8. Department of Pulmonary Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
9. Department of Radiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
10. Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan
11. Edinburgh Imaging, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK

Corresponding Author:
Mark L. Schiebler, M.D.
Professor of Radiology
UW-Madison School of Medicine and Public Health
600 Highland Avenue
Madison, Wisconsin
Telephone: 608-263-1229
Fax:
Email: mschiebler@uwhealth.org
Non-Contrast Chest Computed Tomographic Imaging of Obesity and the Metabolic Syndrome (MetS): Part 1
Cardiovascular Findings

Abstract

There are physiological consequences of overeating that can lead to increased morbidity and mortality. Purpose of this review article is to acquaint the reader with the current state of the art in the non-cardiac gated, non-contrast chest Computed Tomographic (NCCT) imaging biomarkers of the metabolic syndrome (MetS) and their prognostic significance found in the lower neck and chest. NCCT Imaging biomarkers, associated with MetS in the chest include premature coronary artery calcification, acceleration of large vessel arterial and valvular calcifications associated with atherosclerosis, and pulmonary arterial enlargement from pulmonary hypertension associated with sleep apnea. These easily identified imaging biomarkers have prognostic implications for Major Adverse Cardiac Events (MACE). These NCCT chest-imaging biomarkers are likely targets for artificial intelligence algorithms to harvest for longitudinal assessment of their individual and multifactorial contributions to chronic disease, MACE and mortality. Early recognition and treatment of these common disorders may help improve patient outcomes and quality of life while decreasing medical costs.

Key words (Mesh Terms): Humans, Biomarkers, Prognosis, Metabolic Syndrome, Tomography, X-ray computed, Calcium Scoring, Atherosclerosis, Sleep apnea syndrome, Pulmonary Hypertension, Thorax
Abbreviations:

AVC  Aortic Valve leaflet Calcification
CAC  Coronary Artery Calcification
CT  Computed Tomography
DSC Ca++  Descending aorta Calcium value
FR  Framingham Risk Score
HR  Hazard Ratio
HU  Hounsfield unit
LA  Left Atrium
LAD Ca++  Left Anterior Descending coronary artery Calcium value,
LA-MACSA  Left atrial maximal cross-sectional area (mm²)
LV  Left Ventricle
MAC  Mitral valve Annulus Calcification
MACE  Major adverse cardiovascular event
MV CA++  Mitral Valve leaflet Calcification
MetS  Metabolic Syndrome (a.k.a. Syndrome X)
NCCT  Non contrast Computed Tomography
NG-N CCT  Non cardiac Gated, Non-Contrast chest Computed Tomography
OSA  Obstructive Sleep Apnea
PH  Pulmonary Hypertension
mPAP  mean Pulmonary Artery Pressure
RV  Right Ventricle
TAC  Thoracic Aortic Calcification
**Introduction**

Cardiovascular disease (CVD) is the number one cause of mortality with an estimated 17.9 million deaths worldwide in 2015 (1). This represents an increasing problem for public health in both developed and developing countries (1). The metabolic syndrome (MetS) is a complex disorder of metabolism which results in an increased risk for CVD and Type 2 diabetes (2). It is comprised of a cluster of risk factors including elevated blood pressure, dyslipidaemia (lowered high-density lipoprotein (HDL) cholesterol and elevated triglycerides), elevated fasting glucose and central obesity (2). The American Heart Association/ ATP III definition of MetS is dependent on three of the five risk factors being present (2):

- enlarged waist circumference with population-specific and country-specific criteria; triglycerides ≥ 150 mg/dL, HDL-c < 40 mg/dL in men and < 50 mg/dL in women, systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 85 mm Hg and fasting glucose > 100 mg/dL, with the inclusion of patients taking medication to manage hypertriglyceridemia, low HDL-c, hypertension and hyperglycemia.

All parts of the body are affected by MetS. Recently, Bizino et al, reviewed the role of MRI for the study of MetS in the entire body. (3) Work on the gut-brain axis also shows that there is bidirectional signalling between the two organs and that the metabolome in the gut, which is influenced by a high fat/refined sugar diet, has critical roles in host metabolism, the brain reward system and behavior. (4) Put into more mundane terms, “the comfort foods of sugar and fat taste good and the brain wants more than the body needs.” This trend for overindulgence in food and sugar filled, and/or alcoholic drinks, spells trouble for the future of medical care expenditures in the developed world.

The underlying pathophysiology of MetS is related to the induction of low-grade systemic inflammation via increased levels of inflammatory cytokines (e.g. IL-6, IL-1 and TNF-α), adipokines and leptin, which originate from adipocytes or macrophages in the fat tissue. (5) This inflammatory process contributes to atherosclerosis, metabolic dysfunction and results in MetS. This increase in inflammation also effects the lung function by activation of
fibroblasts, endothelial cells of the lung vessels, airway epithelial and smooth muscle cells. This helps to explain why asthma is more severe in obese individuals. (5) Also, insulin resistance increases in asthmatics as insulin alters airway function and structure. (5) Obesity is thus associated with severe asthma induced by low-grade systemic inflammation and insulin resistance, which implies that strategies to treat insulin resistance, obesity and systemic inflammation could work also for asthma. (5, 6)

The prevalence of obesity in adults, defined as BMI >25.0 kg/m², has increased worldwide from 1980 to 2013: in women from 29.8 to 38.0 % and in men from 28.8 to 36.9 %.(7) This problem is not limited to the adult population, as childhood obesity has also become an increasing problem with important future consequences for public health expenditures, morbidity and mortality.(7) Reasons for this increase are high caloric diet, changes of diet composition, changes in microbiome of gut, changes in behaviour and lack of physical exercise.(7) In the developing countries, obesity increased from 8.4 to 13.4 in girls and from 8.1 to 12.9% in boys, while the proportion of obesity in the developed countries meanwhile is 22.6% in girls and 23.8 in boys.(7) As a consequence, cardiovascular dysfunction, diabetes or fatty liver disease with possible progression to end stage liver disease are apparent at an early age.(7-9) As the developed world ages, the health effects of obesity (MetS, Type 2 diabetes, cardiovascular disease and osteoarthritis of the spine, knees and hips) will demand an even larger portion of future public health expenditures.

The purpose of this review is to acquaint radiologists with the current state of the art in the non-cardiac gated, non-contrast chest computed tomography (NG-NCCT) cardiovascular imaging biomarkers found patients with obesity and the metabolic syndrome (MetS) and their prognostic significance. Our aim is to help identify those persons at risk using the metrics from these imaging biomarkers and to then recommend lifestyle interventions (weight reduction, increased physical activity and nutritional intervention) and a modification of medical management or surgery to improve patient outcomes.(10)

Heart and great vessels
The progression of cardiac and vascular disease takes place over decades and is for the most part asymptomatic. Thus, without testing the patient is not aware of the degree of his/her atherosclerotic burden. NG-NCCT can detect and quantify early heart disease and serve as a prognostic marker, particularly in patients with MetS. Madaj and Budoff published a nice summary of the risk stratification that NCCT can provide.\(^\text{(11)}\) Given the limited soft-tissue contrast of non-enhanced CT, most prognostic markers are based on the quantification of calcification - either as part of vascular arteriosclerosis or valve leaflet calcification. While all cardiac structures are affected by cardiac motion, there is increasing evidence that, with newer hardware, and faster gantry rotation times, low-dose NG-NCCT cardiac motion is less of a problem for calcification and myocardial scar assessment/quantification (\textit{Figures 1-4}).\(^\text{(12-15)}\) Furthermore, arteriosclerosis is a systemic disease and although the association is stronger between atherosclerotic alteration and development of further events in the same organ segment (\textit{16}), assessment of one vascular bed may serve as a proxy for an overall risk marker. However, a significant portion of potentially clinically significant cardiovascular findings are currently not mentioned in the written reports, particularly by junior radiologists.\(^\text{(17)}\)

\textbf{Coronary artery Calcification}

The most important non-acute finding on NCCT predictive of future major adverse cardiac events is coronary artery calcification (CAC) (\textit{Figures 2 and 4}). Broad evidence exists regarding the prognostic value of coronary artery calcification (CAC) for cardiovascular events (\textit{18-22}). More importantly, the use of CAC improved risk stratification beyond existing, clinical risk scores. This was conclusively shown in the Heinz-Nixdorf RECALL included 4,487 subjects without known CAD. With the addition of CAC assessment to the Framingham-Risk-Score the area under the curve improved from 0.681 to 0.749 (p<0.003) and when CAC was added to the National Cholesterol Education Panel ATP III categories the area under the curve improved from 0.653 to 0.755 \(^\text{(18)}\). CAC was a much stronger predictor of risk than carotid intima-media thickness, high-sensitivity C reactive protein and the ankle-brachial index \(^\text{(19)}\). Further results from the MESA study showed that CAC improves risk assessment in individuals with family history \(^\text{(19)}\). Consequently, CAC assessment has been incorporated into many clinical guidelines for risk stratification. Depending on the guideline used, CAC is considered an appropriate test to perform in asymptomatic adults at intermediate risk for heart disease. These patients are defined by having a 10%
to 20% 10-year risk or having a Systemic Coronary Risk evaluator (SCORE) (23) risk stratification value range of 5% - 10%, low-risk individuals with a family history of premature disease and all diabetic patients 40 years or older are also candidates for this test. (24-26) Budoff and colleagues (22) have recently shown that in the MESA cohort (N=6814) (https://www.mesa-nhlbi.org/Calcium/input.aspx) for each doubling of CAC there was a 14% increase in CVD risk. They concluded that CAC is highly associated with MACE and this gated non contrast CT biomarker was found to be independent of standard risk factors (Supplementary Table S1). (22)

Evidence based guidelines for the use of CAC are based on publications using cardiac-gated CT. This is because CAC has a high density and is sensitive to motion artefacts leading to false CAC values (27). New technology of multi-detector computed tomography scanners with faster gantry rotation times and thinner detector row widths allow for thinner slices with a reduction in partial volume effects. These changes in hardware now allow for more exact and reliable measurement of CAC on non-gated NCCT scans (NG-NCCT). In a study by Wu et al (28) on 483 patients showed excellent correlation of Agatston CAC scores between a dedicated cardiac gated non-contrast CT for calcium scoring (16 slice multidetector, 3.0 mm slice thickness) and a low dose NG-NCCT (16 slice multidetector, 0.75mm slice thickness) performed for lung cancer screening (Figure 1). In their cohort of NG-NCCT patients the average heart was 61 beats per minute. They did not assess the importance of potential heart rate dependent motion artifact that may limit the accurate quantification of calcium score using non gated CT protocols (28). They found an intraclass correlation coefficient of 0.95 for the agreement between the scores on low-dose NG-NCCT versus the respective routine cardiac-gated CT for CAC in this one observer study. In a study by Kim et al., where 128 patients underwent both non-gated low dose lung cancer screening and ECG-gated CAC scanning, an accuracy of 90% was observed for CAC>0 on the gated CAC scan and the absolute CAC scores correlated well (r=0.89) (29). In a meta-analysis of 661 subjects (3 separate studies) performed in 2013, Xie et al convincingly showed that, when the Agatston Score at non-gated low dose NCCT was compared with the gold standard of routine cardiac gated CT performed for CAC scoring, the pooled correlation coefficient was 0.94 (95%CI: 0.89-0.96). These data are confirmative of the newly available scatter plot from Wu et al (28) (Figure 1) showing a R² of 0.95 between Agatston scores as derived from NG-NCCT versus cardiac gated CT.
While the Agatston score as a continuous measurement has been established for formal CAC assessment, the development of visual scores for CAC categorization is essential in order to provide the chest radiologist with a simple technique that is less time consuming. Several studies have been performed showing that either a visual-qualitative assessment or a visual ordinal scale can be used for reliable and accurate risk assessment as compared to Agatston score (30-32). But more importantly, both Agatston score and/or a visual CAC assessment from NG-NCT have prognostic value for cardiovascular events and overall mortality. In detail, a study performed by Mets et al in 3,648 lung cancer screening patients using an automatically derived Agatston score from NG-NCT in a risk prediction model found overall good discrimination (AUC 0.71) with an event frequency of 12.2% vs 4.0% in the high vs. low risk groups, respectively. In the ECLIPSE trial Williams et al found that CAC was increased in patients with chronic obstructive pulmonary disease and was associated with an increased risk of death. (34) In the National Lung Screening Trial assessing 1,442 patients, an Agatston scores of 1-100, 101-1000, and >1000 had HR of 1.27, 3.57, and 6.63 as derived from NG-NCT and compared to an Agatston score of 0. Interestingly, in a case-control study authored by Hughes-Austin et al. in which both ECG-gated 3 mm and non-gated 6 mm CT scans were available, the predictive value of the Agatston score for mortality where similar. (36) Focusing on visual assessment, Shao et al showed in a single centre study that there is no significant difference in the discriminative power of visual CAC assessment vs. Agatston score (AUC: 0.80, 0.81). (37) Most evidence exist for a visual assessment using an ordinal CAC scoring system categorizing from 0-12 or 0-30 based upon visual estimation (Table 1). The study of Shemesh et al. including 8,782 smokers with 72 months mean follow up showed that this simple ordinal system was strongly predictive for cardiovascular death (32) and further confirmed by Blair et al. to be of similar predictive value as the Agatston score (31) (Table 2). Gonzales et al have recently shown that automated detection of Agatston scores can be derived from NG-NCT exams. (38) Thus, in a common guideline, the Society of Cardiovascular Computed Tomography (SCCT) and the Society of Thoracic Radiology (STR) recommend “the incorporation of CAC into all non-gated non-contrast chest examination reports” since it “in the treatment of coronary artery disease” (39).

It is very clear that coronary artery calcium can be reliably detected on NG-NCT and that either ordinal scoring methods or quantification of the NG-NCT Agatston score are highly correlated (within 10%) with those cardiac gated non-contrast CT exams that are performed only for CAC scoring. **An argument can be made that the**
CAC score value obtained using current state of the art multidetector NG-NCCT of the chest, performed for any reason, are a good proxy for a dedicated CAC scoring CT.

Aortic calcification

The thoracic aorta is another important vascular bed imaged on a standard chest CT. As compared to the coronary arteries, the assessment thoracic aorta calcification (TAC) less standardized but also less effected by cardiac motion. In a retrospective study by Jairam et al. found good predictive value for cardiovascular events when including visual assessment of TAC (HR: 0.37, p<0.001) into a larger predicting model. (40) Similar results were observed in the Heinz Nixdorf RECALL study (41), where TAC together with other CT-derived parameters improved the prediction of events over the Framingham Risk Score and CAC (AUC: 0.749 to 0.764; p=0.01). In contrast, Kim et al found in subjects from the MESA study without CAC (n=3,415) that TAC was associated to cardiovascular events and all-cause mortality, but this association attenuated after adjustment for cardiovascular risk factors. (42) Similarly, in the Framingham Heart Study TAC provided no incremental value above risk factors for the prediction of events. (43) Thus, TAC is a prognostic marker, but its incremental value to traditional risk factors and other CT-findings, particular to CAC remain controversial.

Valvular Calcification

The most common valve affected by calcification is the aortic valve. The aortic valve calcification (AVC) can vary by its degree and/or by its location and can lead to aortic stenosis. The degree of stenosis is increasing with AVC extent, while calcification of the peripheral left-posterior and the central right-left commissural leaflets is particularly correlated with mean and peak gradient increases across the aortic valve. (44) The underlying pathophysiology is complex and integrates lipids, the renin-angiotensin system, inflammation, signalling pathways, and genetic predisposition. (45) Also, a strong linkage to visceral obesity has been described leading the neologism ‘valvulo-metabolic’ risk. (46) Further, AVC shares common risk factors with arteriosclerosis; hence, patients with AVC had more frequently coexisting presence of coronary plaque and had a greater extent of coronary plaque burden (6.4 vs 1.8 segments for patients with and without AVC, P<0.001) as described in a study of 357 subjects undergoing cardiac
Interestingly, AVC was more strongly associated with calcified (OR: 5.2, p=0.004), then with mixed (OR: 3.2, p=0.02) or non-calcified plaque (P=0.96). Several studies have been performed regarding the prognostic value of AVC for cardiovascular events and all-cause mortality. Although AVC showed a prognostic value in univariate analysis, it attenuated in most studies after adjustment for traditional risk factors and after further adjustment for CAC and/or TAC. (43, 48-50)

Annular Calcification

The annulus of the mitral valve is most commonly calcified. Mitral annular calcification (MAC) is a chronic degenerative process in the fibrous base of the mitral valve and more commonly affects the posterior annulus than the anterior annulus. (51) Traditionally, MAC is assessed using echocardiography and several studies using this technology showed independent association of MAC with cardiac events. (52, 53) Given a good relationship in MAC between echocardiography and CT (54), MAC was also a good predictor for cardiovascular events if assessed by CT (55, 56). In the Northern Manhattan Study (n=1,955) (55), MAC prevalence was 27%, while severe MAC (>4mm thickness) was observed in 13%. Presence of MAC was associated with myocardial infarction (HR: 1.75) and cardiac death (HR: 1.53) and these associations became stronger if using severe MAC as the predictor (HR: 1.89 and 1.81; respectively). In this cohort, but also in a cohort with atrial fibrillation, MAC was not significantly associated with cerebrovascular events. (55, 56)

Caseous calcification of the mitral valve is a rare form of MAC. The contents of the hollowed out cavity in the mitral valve annulus is composed of a mixture of calcium, fatty acids, and cholesterol that has a “toothpaste-like” texture. This commonly presents as an intracardiac mass at echocardiography. There is limited evidence regarding the prognostic value of caseous calcification of the mitral annulus. In a literature review of 1,502 articles, Dietl et al. identified a total of 130 patients with caseous calcification of the mitral annulus reported in 86 publications. The prevalence of cerebrovascular events was higher in patients with caseous calcification of the mitral annulus than with simple MAC (19% vs 12%, respectively; p=0.02).

Atrial and Ventricular size
There is a large body of evidence that MetS carries an increased risk of left ventricle (LV) hypertrophy, left atrial (LA) enlargement, systolic and/or diastolic dysfunction, arrhythmias and interstitial myocardial fibrosis. MetS is also associated with increased LV mass and LV diastolic dysfunction.\(^{(57, 58)}\) (Aijaz et al. 2008, Ladeiras-Lopes et al. 2018, Shah et al. 2013) CT can be useful for assessing cardiac chambers to determine their size, shape and thickness. Cardiac gated CT scans can usually be obtained during diastole for CAC scoring and coronary angiography, as this phase of the cardiac cycle has the least motion. While chamber assessment is relatively simple for gated, contrast-enhanced CT scans given existing software tools, NG-NRCT exams are more challenging and an area-based approach has been proposed. Schlett et al. showed that an area-based measurement for LV on axial, non-contrast enhanced CT images correlates well with LV volume, mass and size \((r=0.68; r=0.73; r=0.82)\).\(^{(59)}\) Similar correlations were observed for the left atrium.\(^{(60)}\) In the MESA cohort, such area-based LV measurement of non-contrast CT scans is a predictor of incident heart failure events \((HR 1.15; 95\%CI 1.11-1.20)\) beyond traditional risk factors and CAC score; but also for CHD events \((HR 1.07; 95\%CI 1.03-1.10)\). As RV and LV contraction is usually synchronous, the RV/LV diameter and volume ratios have been used in NG-NRCT studies to assess RV dilation and dysfunction in response to increased RV afterload.\(^{(61)}\) (Henzler et al. 2012, Mansencal et al. 2005) A limited number of reports indicate that RV hypertrophy may parallel alterations in LV structure and function in the setting of systemic hypertension, obesity and diabetes.\(^{(62)}\) All the components of MetS (increased blood pressure, abdominal obesity, increased fasting glucose level and dyslipidemia) may induce right ventricular remodelling by several hemodynamic and non-hemodynamic mechanisms.\(^{(63)}\) Increasing evidence suggests that in pulmonary hypertension (PH) RV dysfunction is associated with various components of MetS, such as insulin resistance, hyperglycemia, and dyslipidemia.\(^{(64)}\)

Regarding LA assessment, an enlarged size was associated with a 3- to 5-fold increase risk for ACS and provided incremental value for predicting ACS when added to the CT finding of indeterminate coronary artery stenosis in a population with acute chest pain presenting to the ED.\(^{(61)}\) In the Heinz-Nixdorf Recall Study \((62)\), LA size had prognostic value \((HR 1.48)\), which remained significant after adjustment for traditional risk factors \((HR 95\%CI: 1.09-1.43)\) and after adjustment for traditional risk factors plus CAC \((HR 95\%CI: 1.07-1.40)\) \((\text{Table 2})\). Prognostic value of LA size was similar for different endpoints (coronary event: HR: 1.21; stroke: 1.31; CV death: 11)
1. LA size also remained associated with cardiovascular events independent of other CT non-coronary findings. Recently Jivraj et al have shown in 165 patients with right heart catheterization proven pulmonary hypertension (PAP > 45 mm Hg) and capillary wedge pressures (43 patients - PCWP > 15 mm Hg, 122 patients PCWP < 15 mm Hg) that left atrial maximal cross-sectional area (LA-MACSA) measured from NG-NCCT (LA-MACSA > 2400mm$^2$, P<0.001) had a 44% sensitivity and 93% specificity for pulmonary hypertension from left heart disease. On NG-NCCT studies the images may not reveal the true ventricular morphology because the phase of the cardiac cycle is unknown. However, a few studies have reported good sensitivity and specificity (both >68%) of standard axial, non-gated chest CT for cardiomyopathies.

Left ventricle

The left ventricle size (volume and in-plane area) can be estimated from NCCT chest exams. Bhatt and colleagues have created an automated process for generating the expected ventricular sizes from NG-NCCT chest exams by comparing these studies to ultrasound and cardiovascular MRI exams that show the ventricular volumes and wall thickness. The assessment of ventricular volume and wall thickness is easier if the patient is anemic, as the ventricular chambers are seen to be of lower Hounsfield unit density than the walls. The presence of prior left ventricular myocardial infarction is also easily determined by the presence of a low density scar. These are typically seen in the subendocardial regions of the wall and may be transmural.

Recently Kockelkoren et al published their data from routine NG-NCCT exams on patients that were studied for non-cardiovascular disease (Tables 3 and 4). This was derived from a rather homogeneous population of Caucasians in the United Kingdom. This group of researchers created a simple to use ordinal grading scale for the determination of future major adverse cardiac events (MACE) and have a computational model for the likelihood of a major cardiac event within 5 years that is based on a best fit multivariable regression model (Supplementary Tables S2, S3). The parameters include: age, male gender, indication for exam, left anterior descending coronary artery calcium (LAD Ca++), mitral valve leaflet calcification (MV CA++) value, descending aorta calcium value (DSC Ca++), and the maximum transverse diameter (cm) of the heart.

Epicardial Fat
In their study of 3,630 subjects from the Heinz-Nixdorf Recall Study, Mahabadi et al. (41) found that the epicardial fat volume (HR: 1.15, 95% CI 1.01-1.30, p value 0.03), was an imaging biomarker predictive of myocardial infarction, stroke and cardiovascular death (Table 5). In their systematic review, Bertaso et al. found that the heterogeneity of the studies limits the conclusions that can be drawn from using this metric. They found that this visceral fat deposit is highly correlated with obesity, diabetes mellitus, age and hypertension. Manno et al. showed that epicardial fat thickness at ultrasound was correlated with higher LDL cholesterol.(66) In their study from 2018, Hedgire et al. show that perivascular fat stranding, seen on coronary CT angiography is associated with high risk clinical features and they suggest that fat stranding is a potential imaging biomarker of high-risk and/or ruptured atherosclerotic plaques.(67) Hartila et al. found no evidence that increased epicardial fat volume was independently associated with pre-clinical atherosclerosis.(68) Instead, they found that epicardial fat volume was primarily associated with BMI and waist circumference.(68) Furthermore, there is increasing evidence that fat quality rather than fat volume may play a role in the association to CVD. (69)

Pulmonary artery diameter predicts pulmonary hypertension

Sleep disordered breathing (sleep apnea) is an important cause of pulmonary hypertension.(70) Obstructive Sleep Apnea (OSA) is caused by the increased collapsibility of the upper airway from loss of muscle tone and a decrease in the effective orifice from fat deposition in the tongue and surrounding pharynx during sleep.(71) This results in decreased or absent airflow and hypoxia. These episodes are usually terminated by a brief arousal from sleep and resulting in sleep deprivation for subjects with MetS.(72) Over many years, these apneic episodes lead to sleep fragmentation and altered cognitive function. (73) These episodes of hypoxia are associated with pulmonary artery vasoconstriction and can lead to permanent changes in PA size (Figure 5). (74) Corson et al. studied 175 subjects with right heart catheterization (RHC) proven pulmonary hypertension (PH), 16 normal patients with proven normal mean pulmonary artery pressures (mPAP) and 114 subjects without known mPAP and found a sensitivity of the criterion “mean pulmonary artery diameter at the level of the bifurcation >29mm” was 0.89 (95% CI 0.84-0.93) and a specificity of 0.83 (95%CI: 0.76-0.90). (75) Truong et al. studied 706 “healthy cohort” subjects in the Framingham Heart Study using cardiac gated NCCT and found a 90th percentile cut-off value of 28.9 mm in men and 26.9 mm in women. (76) Pulmonary artery diameter is an important clue that may indicate pulmonary
hypertension from any cause (77), and in the setting of obesity or MetS an enlarged PA can be used to alert the imager and clinician to the possibility for OSA. Instituting treatment with Continuous Positive Airway Pressure (CPAP) can significantly improve the length and quality of life for these individuals.

Radiation dose and safety using NG-N CCT for the diagnosis of MetS

We are not proposing to use NCCT for the diagnosis of MetS or obesity. From studies performed for other indications, the imaging physician can also make inferences about the metabolic milieu of that subject based on the multiple imaging findings discussed in this review. For the most part, low dose chest CT protocols are very low contributors to the medical radiation any patient receives over the course of their lifetime (78). Each scan delivers between 0.5 and 5 mSv depending on the patient size, use of dose lowering reconstruction methods and automatic exposure control (limit mAs) (79).

Conclusion

The beauty of non-gated, non-contrast computed of the chest is that quantitative assessment of Hounsfield unit density, contour and volume of many organs can be assessed longitudinally and correlated to patient outcomes. This differs substantially from contrast enhanced CT data, because there is no iodinated contrast material confounding the density measurements. There are easy to access imaging biomarkers associated with obesity, atherosclerotic disease and MetS that are routinely seen on these exams. The most important one found on NG-N CCT is coronary artery calcification. Various models combining clinical and imaging data have been shown to have prognostic significance for Major Adverse Cardiac Events. Thus, these exams are a virtual treasure trove of quantitative imaging biomarker information available for retrospective analysis to create survival models (training sets) that can be applied prospectively to test sets and validated with external data sets. These big data can be added to radiomic feature analysis, convolutional neural networks and/or added to deep neural networks without any user defined features to create better survival models that can be used to help design personalized medical interventions aimed at prolonging quality life expectancy.
References


80. Shemesh J. Coronary artery calcification in clinical practice: what we have learned and why should it routinely be reported on chest CT? Ann Transl Med. 2016;4(8):159.
Data from Wu et al (28) in a study comparing Agatston Calcium Scores on non-cardiac gated, non-contrast low dose CT (LDCT) performed for lung cancer screening to standard cardiac gated, non-contrast computed tomography (NCCT) in 513 consecutive cases. This shows excellent correlation between these two ways to quantify Agatston coronary artery calcification scores (R²=0.95). They found a systematic under quantification of CAC using LDCT (y intercept = -12.1). Thus, any coronary artery calcification found at LDCT is worthy of quantification. This can be performed either by ordinal scoring or using post processing to obtain the non-cardiac gated LDCT Agatston score. (Scatter plot of the raw data made expressly for this article by Ming-Ting Wu, M.D.)

Legend Figure 2: Non-gated, non-contrast computed tomography of the chest with globular calcification of an atherosclerotic plaque at the origin of the left anterior descending coronary artery (arrow head).

Legend Figure 3: Non-gated, non-contrast computed tomography of the chest coned down to the heart (A) axial and (B) short axis reconstruction showing a fibrofatty subendocardial scar (arrows) in the left ventricular septum, inferior and inferolateral walls from an old myocardial infarction in the right coronary artery vascular territory. Note the presence of hepatic steatosis as well (A) with a liver density of 35 Hounsfield units (ROI -Region of interest).

Legend Figure 4: 45 year old Caucasian male with (A) borderline evidence for low iodine organification in the thyroid with a thyroid density of 64 (Normal range 80-120 HU) (B) non gated Agatston score of 2 is at least in the 79th percentile for age and sex. There was hepatic steatosis as well (C) with a liver density of 42.9 HU. The
paraspinous muscle density was low measuring 33.8 HU at the T12 level (Normal range 5-60HU, from unpublished data (Tsuchiya et al, submitted)). This constellation of findings is the imaging equivalent of the clinically defined Metabolic Syndrome and suggests both glucose intolerance and an increase in overall inflammatory cytokines due to the low paraspinous muscle density.

Legend Figure 5: Pulmonary trunk measured at the largest part of the right main pulmonary artery is 4.0 cm (white line). This is abnormal and is suggestive of the possibility of pulmonary hypertension/pulmonary arterial hypertension. In an obese individual a common cause is sleep disordered breathing (sleep apnea) which can be treated with a night time Continuous Positive Airway Pressure (CPAP) mask.

Legend Supplemental Figure 1: Automatic segmentation of the left and right ventricular cavities from non contrast non cardiac gated chest CT exams using the method of Bhatt et al (65). (A) axial chest CT with the estimated left ventricle cavity in light red and the estimated left ventricular wall in dark red, with the estimated right ventricle in blue, (B) sagittal non contrast CT showing the estimated left ventricle in red and the estimated right ventricle in blue. (C) coronal chest CT showing the estimated left ventricle in red and the estimated right ventricle in blue, (D) Entire volume of left ventricle in red and right ventricle in blue.

Legend Table 1: Importance of coronary artery calcification found on non-cardiac gated chest computed tomography in patients that smoke cigarettes (table modified from Shemesh et al) (80) Practical comments for chest radiologists showing that the larger ordinal coronary artery calcium score is associated with an increased risk of Major Adverse Cardiac Events. (This table is modified from Shemesh et al (80)) Abbreviations: CAC- coronary artery calcium score; Visual Score (Likert Scale range from 0-12); CAD- coronary artery disease, PVD- peripheral vascular disease;

Legend Table 2: Imaging findings on non-contrast, non-cardiac gated Chest Computed tomography exams that are reflective of individual biology and the metabolic syndrome. (Abbreviations: n-number affected. N=total in study)

Legend Table 3: Imaging based cardiovascular risk biomarkers derived from a Caucasian population in Scotland (N=2124) (81). This type of analytic approach to documenting vascular calcifications was first used by Jairam et al in 2014 (40).

Legend Table 4: Hazard Ratios for the most significant model parameters for determining cardiovascular risk from contrast enhanced, non-gated chest CT exams from the PROVIDI study (N=10,410) (40).

Legend Table 5: Multivariable analysis of clinical and imaging based cardiovascular risk biomarkers derived from 3,630 subjects enrolled in the prospectively acquired Hienz-Nixdorf Recall Study. (41) and their adjusted Hazard Ratios for the interval development of major adverse cardiac events (MACE). (Abbreviations: FR- Framingham Risk Score, CAC- Coronary artery Agatston Score.)

Legend Table S1: Multi-Ethnic Study of Atherosclerosis (MESA) results from Budoff et al(22) modified from Table 2 in the original publication, showing the ten year event rate of major adverse cardiac events based simply off of the gated CT chest coronary artery Agatston calcium scores. These event rates are not adjusted for any clinical risk factors. These data show the effects of CAC transcend age related changes; in that more CAC is worse than simply being old. The Chinese and Caucasian were less affected by CAC than African-Americans and Hispanics.

Legend Tables S2 and S3: Kockelkoren (81) Scottish heart study risk 10 year estimated risk model (Table S2) and the equation used to derive the 5 year risk score (Table S3)
Figure 1: Data from Wu et al (28) in a study comparing Agatston Calcium Scores on non-cardiac gated, non-contrast low dose CT (LDCT) performed for lung cancer screening to standard cardiac gated, non-contrast computed tomography (NCCT) in 483 cases. This shows excellent correlation between these two ways to quantify Agatston coronary artery calcification scores ($R^2=0.95$). They found a systematic under quantification of CAC using LDCT ($y$ intercept = -12.1). Thus, any coronary artery calcification found at LDCT is worthy of quantification. This can be performed either by ordinal scoring or, as in this study, using post processing to obtain the non-cardiac gated LDCT Agatston score. (Scatter plot of the raw data from (28) made expressly for this article by Ming-Ting Wu, M.D.)
Legend Figure 2: Non gated, non-contrast computed tomography of the chest with globular calcification of an atherosclerotic plaque at the origin of the left anterior descending coronary artery (arrow head).
Legend Figure 3: Non gated, non-contrast computed tomography of the chest coned down to the heart (A) axial and (B) short axis reconstruction showing a fibrofatty subendocardial scar (arrows) in the left ventricular septum, inferior and inferolateral walls from an old myocardial infarction in the right coronary artery vascular territory. Note the presence of hepatic steatosis as well (A) with a liver density of 35 Hounsfield units (ROI - Region of interest).
Legend Figure 4: 45 year old Caucasian male with (A) borderline evidence for low iodine organification in the thyroid with a thyroid density of 64 (Normal range 80-120 HU) (B) non gated Agatston score of 2 is at least in the 79th percentile for age and sex. There was hepatic steatosis as well (C) with a liver density of 42.9 HU. The paraspinous muscle density was low measuring 33.8 HU at the T12 level (Normal range 5-60HU, from unpublished data (Tsuchiya et al, submitted)). This constellation of findings is the imaging equivalent of the clinically defined Metabolic Syndrome and suggests both glucose intolerance and an increase in overall inflammatory cytokines due to the low paraspinous muscle density.
Legend Figure 5: Pulmonary trunk measured at the largest part of the right main pulmonary artery is 4.0 cm (white line). This is abnormal and is suggestive of the possibility of pulmonary hypertension/pulmonary arterial hypertension. In an obese individual a common cause is sleep disordered breathing (sleep apnea) which can be treated with a night time Continuous Positive Airway Pressure (CPAP) mask.
Legend Supplemental Figure 1: Automatic segmentation of the left and right ventricular cavities from non contrast non cardiac gated chest CT exams using the method of Bhatt et al (65). (A) axial chest CT with the estimated left ventricle cavity in light red and the estimated left ventricular wall in dark red, with the estimated right ventricle in blue, (B) sagittal non contrast CT showing the estimated left ventricle in red and the estimated right ventricle in blue, (C) coronal chest CT showing the estimated left ventricle in red and the estimated right ventricle in blue, (D) Entire volume of left ventricle in red and right ventricle in blue.

Tables
Table 1: Importance of coronary artery calcification found on non-cardiac gated chest computed tomography in patients that smoke cigarettes (table modified from Shemesh et al) (80) Practical comments for chest radiologists showing that the larger ordinal coronary artery calcium score is associated with an increased risk of Major Adverse Cardiac Events. (This table is modified from Shemesh et al (80)) Abbreviations: CAC- coronary artery calcium score; Visual Score (Likert Scale range from 0-12); CAD- coronary artery disease, PVD- peripheral vascular disease;

<table>
<thead>
<tr>
<th>No CAC</th>
<th>0</th>
<th>0</th>
<th>More favorable prognosis for CV events; More favorable prognosis for CV events; The presence of chronic obstructive CAD is very unlikely, life style changes</th>
<th>Might be false negative since small calcific lesions are missed (Agatston score &lt;10); the visual score is less sensitive in subjects with low CAC burden</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild CAC</td>
<td>1-100</td>
<td>1-4</td>
<td>Mildly increased risk for CV event</td>
<td>Consider further coronary evaluation and primary preventive treatment according to the patient global risk, life style changes should be more emphasized.</td>
</tr>
<tr>
<td>Moderate CAC</td>
<td>101-400</td>
<td>5-7</td>
<td>Mildly increased risk of CV event</td>
<td>Consider further coronary evaluation and primary preventive treatment according to the patient global risk and clinical manifestations; in patients with Framingham risk intermediate and above (≥10% in 10 years) statin therapy should be highly considered.</td>
</tr>
<tr>
<td>Severe CAC</td>
<td>&gt;400</td>
<td>8-12</td>
<td>Significantly increases the CV risk and total mortality</td>
<td>In asymptomatic subjects, consider further coronary evaluation by stress ECG, stress echo or SPECT imaging to R/O obstructive CAD; statin therapy should be highly considered. Mostly prevalent in old patients and in those with clinical CAD, PVD and renal failure</td>
</tr>
</tbody>
</table>

Table 1:
<table>
<thead>
<tr>
<th>Non contrast, Chest CT finding</th>
<th>Index cases( n)/ Normal Values (N)</th>
<th>Abnormal Value [n/N]</th>
<th>Unadjusted Hazard Ratio For MACE or Death (95% C.I) <em>p value</em></th>
<th>Adjusted Hazard Ratio (95% CI) <em>p value</em></th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart</td>
<td>Transverse diameter of heart</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left Atrial Index, mm²/m²</td>
<td>917 ±187 [3389/3630]</td>
<td>992 ± 214 [241/3630]</td>
<td>1.42 (1.27-1.59) <em>&lt;0.0001</em></td>
<td>1.18 (1.02-1.37) <em>0.023</em></td>
<td>Gated exam Mahabadi 2016</td>
</tr>
<tr>
<td>Left Ventricular Index, mm²/m²</td>
<td>2,146 ± 275 [3389/3630]</td>
<td>2,240 ± 305 [241/3630]</td>
<td>1.36 (1.21-1.52) <em>&lt;0.0001</em></td>
<td>1.08 (0.93-1.25) <em>0.31</em></td>
<td>Gated exam Mahabadi 2016</td>
</tr>
<tr>
<td>Epicardial Fat Volume, ml</td>
<td>92.7 ± 46.0 [3389/3630]</td>
<td>117.5 ± 55.6 [241/3630]</td>
<td>1.52 (1.38-1.68) <em>&lt;0.0001</em></td>
<td>1.18 (1.02-1.34) <em>0.023</em></td>
<td>Gated exam Mahabadi 2016 &lt;0.0001</td>
</tr>
<tr>
<td>Non Gated Coronary artery Calcifications Ordinal Score</td>
<td>Chiles</td>
<td>Consensus statement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------------</td>
<td>----------------</td>
<td>---------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Non Gated Coronary artery Calcifications Volume     | Consensus statement |

| Non Gated Coronary artery Calcifications Agatston Score | Consensus statement |

| Ascending or Descending Aortic Calcification Cap++ present | 61.5% [2083/3630] | 77.2% [186/241] | 2.08 (1.54-2.81) _0.0001_ | 1.14 (0.83-1.57) _0.41_ | Gated exam Mahabadi 2016 (<0.0001) |

| Aortic Valve Calcifications Ca++ Present | 10.3% [324/3,389] | 19.9% [48/241] | 2.34 (1.7-3.2) _0.0001_ | 1.03 (0.73-1.44) _0.88_ | Gated exam Mahabadi 2016 |

| Ascending Aortic Diameter at Pul Art bifurcation | 35.5 ± 4.0 [3389/3630] | 37.1 ± 4.1 [241/3630] | 1.44 (1.29-1.61) _0.0001_ | 1.02 (0.94-1.06) _0.25_ | Gated exam Mahabadi 2016 |

| Descending Aortic Diameter (mm) at Pul Art bifurcation | 26.5 ±2.9 [3389/3630] | 27.9 ±2.7 [241/3630] | 1.56 (1.39-1.76) _<0.0001_ | 0.94 (0.88-1.03) _0.06_ | Gated exam Mahabadi 2016 |

| Mitral Valve Leaflet Calcium | Andreas H. Mahnken1,2 |

| Mitral Valve Annulus Calcium | Gated exam Mahabadi 2016 |

Legend Table 2: Imaging findings on non-contrast, non-cardiac gated Chest Computed tomography exams that are reflective of individual biology and the metabolic syndrome. (Abbreviations: n= number affected. N=total in study)
<table>
<thead>
<tr>
<th>NCCT imaging Finding</th>
<th>Absent Score=0</th>
<th>Mild Score=1</th>
<th>Moderate Score=2</th>
<th>Severe Score=3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left anterior descending coronary artery calcification</td>
<td>none</td>
<td>1 or 2 calcified plaques limited to 2 or fewer images</td>
<td>Greater than 2 focal plaques or calcification extending for more than 2 slices</td>
<td>Fully calcified coronary artery extending for more than 3 slices</td>
</tr>
<tr>
<td>Descending Thoracic Aorta Calcification</td>
<td>none</td>
<td>Less than or equal to 3 focal calcified plaques</td>
<td>4-5 focal calcified plaques or one plaque extending for 3 or more slices</td>
<td>More than 5 focal calcified plaques or 2 plaques extending beyond 3 slices</td>
</tr>
<tr>
<td>Mitral valve leaflet Calcification</td>
<td>none</td>
<td>One leaflet calcified</td>
<td>Two leaflets calcified</td>
<td></td>
</tr>
</tbody>
</table>
Legend Table 3: Imaging based cardiovascular risk biomarkers derived from a Caucasian population in Scotland (N=2124) (81). This type of analytic approach to documenting vascular calcifications was first used by Jairam et al in 2014 (40).

Table 4

<table>
<thead>
<tr>
<th>Model feature</th>
<th>Hazard Ratio</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>1.41</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Descending Aorta Calcification</td>
<td>1.45</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mitral Valve Calcification</td>
<td>1.25</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LAD Calcification</td>
<td>1.11</td>
<td>&lt;0.003</td>
</tr>
<tr>
<td>(Maximum Transverse Cardiovascular diameter in cm - 11cm$^2$)</td>
<td>1.03</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age</td>
<td>1.03</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Legend Table 4: Hazard Ratios for the most significant model parameters for determining cardiovascular risk from contrast enhanced, non-gated chest CT exams from the PROVIDI study (N=10,410) (40).
Table 5

<table>
<thead>
<tr>
<th>Model feature</th>
<th>Hazard Ratio</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adjusted for FR score, CAC score and Multiple CT measures (95% C.I.)</td>
<td></td>
</tr>
<tr>
<td>Left atrial index</td>
<td>1.21</td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td>(1.07-1.36)</td>
<td></td>
</tr>
<tr>
<td>Left ventricular index</td>
<td>1.15</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>(1.02-1.29)</td>
<td></td>
</tr>
<tr>
<td>Epicardial Fat Volume</td>
<td>1.14</td>
<td>0.04</td>
</tr>
<tr>
<td></td>
<td>(1.01-1.28)</td>
<td></td>
</tr>
<tr>
<td>Presence of Thoracic Aortic Calcification</td>
<td>1.14</td>
<td>0.43</td>
</tr>
<tr>
<td></td>
<td>(0.83-1.56)</td>
<td></td>
</tr>
<tr>
<td>Diameter of Ascending aorta</td>
<td>0.98</td>
<td>0.25</td>
</tr>
<tr>
<td></td>
<td>(0.84-1.15)</td>
<td></td>
</tr>
</tbody>
</table>
Legend Table 5: Multivariable analysis of clinical and imaging based cardiovascular risk biomarkers derived from 3,630 subjects enrolled in the prospectively acquired Hienz-Nixdorf Recall Study, (41) and their adjusted Hazard Ratios for the interval development of major adverse cardiac events (MACE). (Abbreviations: FR- Framingham Risk Score, CAC- Coronary artery Agatston Score.)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Hazard Ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aortic Valve Calcification</td>
<td>1.01</td>
<td>(0.72-1.40)</td>
</tr>
<tr>
<td>Diameter of the Descending thoracic Aorta</td>
<td>0.98</td>
<td>(0.84-1.15)</td>
</tr>
<tr>
<td>Mitral Annulus Calcification</td>
<td>0.81</td>
<td>(0.43-1.54)</td>
</tr>
<tr>
<td>CAC 0</td>
<td>CAC 1-100</td>
<td>CAC 101-300</td>
</tr>
<tr>
<td>-------</td>
<td>-----------</td>
<td>-------------</td>
</tr>
<tr>
<td>Ten year event rate</td>
<td>Ten year event rate</td>
<td>Ten year event rate</td>
</tr>
</tbody>
</table>
Ages 75-85 | 5.6 | 14.3 | 18.1 | 24.7 |
African-American | 3.9 | 7.7 | 14.7 | 24.5 |
Hispanic | 3.1 | 10.3 | 19.1 | 21.7 |
Not On Lipid lowering meds(baseline) | 2.7 | 7.7 | 13.4 | 19.9 |
Female | 2.8 | 7.3 | 10.6 | 19.0 |
Male | 3.0 | 8.0 | 14.4 | 18.2 |
Ages 55-64 | 3.1 | 6.5 | 8.6 | 16.7 |
On lipid lowering agents at baseline | 2.8 | 7.4 | 12.9 | 16.5 |
Ages 45-54 | 1.7 | 3.8 | 15.4 | 16.2 |
Caucasian | 2.4 | 7.3 | 10.8 | 16.2 |
Ages 65-74 | 4.2 | 8.3 | 11.8 | 15.0 |
Chinese | 1.3 | 4.7 | 8.3 | 13.1 |

Legend Table S1: Multi-Ethnic Study of Atherosclerosis (MESA) results from Budoff et al.(22) modified from Table 2 in the original publication, showing the ten year event rate of major adverse cardiac events based simply off of the gated CT chest coronary artery Agatston calcium scores. These event rates are not adjusted for any clinical risk factors. These data show the effects of CAC transcend age related changes; in that more CAC is worse than simply being old. The Chinese and Caucasian were less affected by CAC than African-Americans and Hispanics.

Supplementary Table S2:

Kockelkoren risk model (81)

Predicted vs Observed 10 year cardiovascular risk

<table>
<thead>
<tr>
<th>Risk Group</th>
<th>10y Risk: Radiological risk score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk group (&lt;10% risk)</td>
<td>200 [9]</td>
</tr>
<tr>
<td>No. of patients n (%)</td>
<td>Observed Kaplan-Meier risk (%)</td>
</tr>
<tr>
<td>200 [9]</td>
<td>9.8%</td>
</tr>
<tr>
<td>Intermediate risk group (10-20% risk)</td>
<td>523 [25]</td>
</tr>
<tr>
<td>No. of patients n (%)</td>
<td>Observed Kaplan-Meier risk (%)</td>
</tr>
<tr>
<td>523 [25]</td>
<td>18.8%</td>
</tr>
</tbody>
</table>
High risk group (>20% risk)

<table>
<thead>
<tr>
<th>No. of patients n (%)</th>
<th>1401 (66)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observed Kaplan-Meier risk (%)</td>
<td>36.5%</td>
</tr>
</tbody>
</table>

* 10y observed CVD risk was obtained by extrapolating the cumulative baseline hazard function

Legend Tables S2 and S3: Kockelkoren (81) Scottish heart study risk 10 year estimated risk model (Table S2) and the equation used to derive the 5 year risk score (Table S3)

Supplementary Table S3

Model parameters (81)

5-year cardiovascular disease event risk (%) = \[1 - 0.88^{[\text{A} - 2.16]}\] x 100%

\[A = (0.027 \times \text{Age}) + (0.34 \text{ if male gender}) - (0.33 \text{ if CT-indication hematological malignancies}) - (0.34 \text{ if CT-indication mediastinal abnormalities}) - (0.27 \text{ if CT-indication suspicion pulmonary malignancy}) + (0.034 \text{ if CT-indication suspicion pulmonary embolism}) - (0.30 \text{ if other CT-indication}) + (0.10 \times \text{score [LAD calc]}) + (0.22 \times \text{score [MV calc]}) + (0.37 \times \text{DSC calc}) + (0.02 \times \text{Cardiac diameter}\* - 11\text{cm})^2\]

* Cardiac diameters below 11 cm get value "0", from higher diameters subtract 11 and square the resulting value.

Legend Tables S2 and S3: Kockelkoren (81) Scottish heart study risk 10 year estimated risk model (Table S2) and the equation used to derive the 5 year risk score (Table S3)
Non-Contrast Chest Computed Tomographic Imaging of Obesity and the Metabolic Syndrome (MetS): Part 1
Cardiovascular Findings
Abstract

There are physiological consequences of overeating that can lead to increased morbidity and mortality. Purpose of this review article is to acquaint the reader with the current state of the art in the non-cardiac gated, non-contrast chest Computed Tomographic (NCCT) imaging biomarkers of the metabolic syndrome (MetS) and their prognostic significance found in the lower neck and chest. NCCT Imaging biomarkers, associated with MetS in the chest include premature coronary artery calcification, acceleration of large vessel arterial and valvular calcifications associated with atherosclerosis, and pulmonary arterial enlargement from pulmonary hypertension associated with sleep apnea. These easily identified imaging biomarkers have prognostic implications for Major Adverse Cardiac Events (MACE). These NCCT chest-imaging biomarkers are likely targets for artificial intelligence algorithms to harvest for longitudinal assessment of their individual and multifactorial contributions to chronic disease, MACE and mortality. Early recognition and treatment of these common disorders may help improve patient outcomes and quality of life while decreasing medical costs.

Key words (Mesh Terms): Humans, Biomarkers, Prognosis, Metabolic Syndrome, Tomography, X-ray computed, Calcium Scoring, Atherosclerosis, Sleep apnea syndrome, Pulmonary Hypertension, Thorax
**Abbreviations:**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVC</td>
<td>Aortic Valve leaflet Calcification</td>
</tr>
<tr>
<td>CAC</td>
<td>Coronary Artery Calcification</td>
</tr>
<tr>
<td>CT</td>
<td>Computed Tomography</td>
</tr>
<tr>
<td>DSC Ca++</td>
<td>DeSCending aorta Calcium value</td>
</tr>
<tr>
<td>FR</td>
<td>Framingham Risk Score</td>
</tr>
<tr>
<td>HR</td>
<td>Hazard Ratio</td>
</tr>
<tr>
<td>HU</td>
<td>Hounsfield unit</td>
</tr>
<tr>
<td>LA</td>
<td>Left Atrium</td>
</tr>
<tr>
<td>LAD Ca++</td>
<td>Left Anterior Descending coronary artery Calcium value,</td>
</tr>
<tr>
<td>LA-MACSA</td>
<td>Left atrial maximal cross-sectional area (mm²)</td>
</tr>
<tr>
<td>LV</td>
<td>Left Ventricle</td>
</tr>
<tr>
<td>MAC</td>
<td>Mitral valve Annulus Calcification</td>
</tr>
<tr>
<td>MACE</td>
<td>Major adverse cardiovascular event</td>
</tr>
<tr>
<td>MV CA++</td>
<td>Mitral Valve leaflet Calcification</td>
</tr>
<tr>
<td>MetS</td>
<td>Metabolic Syndrome (a.k.a. Syndrome X)</td>
</tr>
<tr>
<td>NCCT</td>
<td>Non contrast Computed Tomography</td>
</tr>
<tr>
<td>NG-NCCCT</td>
<td>Non cardiac Gated, Non-Contrast chest Computed Tomography</td>
</tr>
<tr>
<td>OSA</td>
<td>Obstructive Sleep Apnea</td>
</tr>
<tr>
<td>PH</td>
<td>Pulmonary Hypertension</td>
</tr>
<tr>
<td>mPAP</td>
<td>mean Pulmonary Artery Pressure</td>
</tr>
<tr>
<td>RV</td>
<td>Right Ventricle</td>
</tr>
<tr>
<td>TAC</td>
<td>Thoracic Aortic Calcification</td>
</tr>
</tbody>
</table>
Introduction

Cardiovascular disease (CVD) is the number one cause of mortality with an estimated 17.9 million deaths worldwide in 2015 (1). This represents an increasing problem for public health in both developed and developing countries (1). The metabolic syndrome (MetS) is a complex disorder of metabolism which results in an increased risk for CVD and Type 2 diabetes (2). It is comprised of a cluster of risk factors including elevated blood pressure, dyslipidaemia (lowered high-density lipoprotein (HDL) cholesterol and elevated triglycerides), elevated fasting glucose and central obesity (2). The American Heart Association/ATP III definition of MetS is dependent on three of the five risk factors being present (2):

- enlarged waist circumference with population-specific and country-specific criteria;
- triglycerides ≥ 150 mg/dL, HDL-c < 40 mg/dL in men and < 50 mg/dL in women;
- systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 85 mm Hg and fasting glucose > 100 mg/dL, with the inclusion of patients taking medication to manage hypertriglyceridemia, low HDL-c, hypertension and hyperglycemia.

All parts of the body are affected by MetS. Recently, Bizino et al, reviewed the role of MRI for the study of MetS in the entire body (3). Work on the gut-brain axis also shows that there is bidirectional signalling between the two organs and that the metabolome in the gut, which is influenced by a high fat/refined sugar diet, has critical roles in host metabolism, the brain reward system and behavior. (4) Put into more mundane terms, “the comfort foods of sugar and fat taste good and the brain wants more than the body needs.” This trend for overindulgence in food and sugar filled, and/or alcoholic drinks, spells trouble for the future of medical care expenditures in the developed world.

The underlying pathophysiology of MetS is related to the induction of low-grade systemic inflammation via increased levels of inflammatory cytokines (e.g. IL-6, IL-1 and TNF-α), adipokines and leptin, which originate from adipocytes or macrophages in the fat tissue. (5) This inflammatory process contributes to atherosclerosis, metabolic dysfunction and results in MetS. This increase in inflammation also effects the lung function by activation of
fibroblasts, endothelial cells of the lung vessels, airway epithelial and smooth muscle cells. This helps to explain why asthma is more severe in obese individuals. (5) Also, insulin resistance increases in asthmatics as insulin alters airway function and structure. (5) Obesity is thus associated with severe asthma induced by low-grade systemic inflammation and insulin resistance, which implies that strategies to treat insulin resistance, obesity and systemic inflammation could work also for asthma. (5, 6)

The prevalence of obesity in adults, defined as BMI >25.0 kg/m², has increased worldwide from 1980 to 2013: in women from 29.8 to 38.0 % and in men from 28.8 to 36.9 %. (7) This problem is not limited to the adult population, as childhood obesity has also become an increasing problem with important future consequences for public health expenditures, morbidity and mortality. (7) Reasons for this increase are high caloric diet, changes of diet composition, changes in microbiome of gut, changes in behaviour and lack of physical exercise. (7) In the developing countries, obesity increased from 8.4 to 13.4 in girls and from 8.1 to 12.9 % in boys, while the proportion of obesity in the developed countries meanwhile is 22.6 % in girls and 23.8 in boys. (7) As a consequence, cardiovascular dysfunction, diabetes or fatty liver disease with possible progression to end stage liver disease are apparent at an early age. (7-9) As the developed world ages, the health effects of obesity (MetS, Type 2 diabetes, cardiovascular disease and osteoarthritis of the spine, knees and hips) will demand an even larger portion of future public health expenditures.

The purpose of this review is to acquaint radiologists with the current state of the art in the non-cardiac gated, non-contrast chest computed tomography (NG-NCT) cardiovascular imaging biomarkers found patients with obesity and the metabolic syndrome (MetS) and their prognostic significance. Our aim is to help identify those persons at risk using the metrics from these imaging biomarkers and to then recommend lifestyle interventions (weight reduction, increased physical activity and nutritional intervention) and a modification of medical management or surgery to improve patient outcomes. (10)

Heart and great vessels
The progression of cardiac and vascular disease takes place over decades and is for the most part asymptomatic. Thus, without testing the patient is not aware of the degree of his/her atherosclerotic burden. NG-NCCT can detect and quantify early heart disease and serve as a prognostic marker, particularly in patients with MetS. Madaj and Budoff published a nice summary of the risk stratification that NCCT can provide. Given the limited soft-tissue contrast of non-enhanced CT, most prognostic markers are based on the quantification of calcification - either as part of vascular arteriosclerosis or valve leaflet calcification. While all cardiac structures are affected by cardiac motion, there is increasing evidence that, with newer hardware, and faster gantry rotation times, low-dose NG-NCCT cardiac motion is less of a problem for calcification and myocardial scar assessment/quantification. Furthermore, arteriosclerosis is a systemic disease and although the association is stronger between atherosclerotic alteration and development of further events in the same organ segment, assessment of one vascular bed may serve as a proxy for an overall risk marker. However, a significant portion of potentially clinically significant cardiovascular findings are currently not mentioned in the written reports, particularly by junior radiologists.

Coronary artery Calcification

The most important non-acute finding on NCCT predictive of future major adverse cardiac events is coronary artery calcification (CAC). Broad evidence exists regarding the prognostic value of coronary artery calcification (CAC) for cardiovascular events. More importantly, the use of CAC improved risk stratification beyond existing, clinical risk scores. This was conclusively shown in the Heinz-Nixdorf RECALL included 4,487 subjects without known CAD. With the addition of CAC assessment to the Framingham-Risk-Score the area under the curve improved from 0.681 to 0.749 (p<0.003) and when CAC was added to the National Cholesterol Education Panel ATP III categories the area under the curve improved from 0.653 to 0.755. CAC was a much stronger predictor of risk than carotid intima-media thickness, high-sensitivity C reactive protein and the ankle-brachial index. Further results from the MESA study showed that CAC improves risk assessment in individuals with family history. Consequently, CAC assessment has been incorporated into many clinical guidelines for risk stratification. Depending on the guideline used, CAC is considered an appropriate test to perform in asymptomatic adults at intermediate risk for heart disease. These patients are defined by having a 10%
to 20% 10-year risk or having a Systemic Coronary Risk evaluator (SCORE) (23) risk stratification value range of 5% - 10%, low-risk individuals with a family history of premature disease and all diabetic patients 40 years or older are also candidates for this test. (24-26) Budoff and colleagues (22) have recently shown that in the MESA cohort (N=6814) (https://www.mesa-nhlbi.org/Calcium/input.aspx ) for each doubling of CAC there was a 14% increase in CVD risk. They concluded that CAC is highly associated with MACE and is this gated non contrast CT biomarker was found to be independent of standard risk factors (Supplementary Table S1).(22)

Evidence based guidelines for the use of CAC are based on publications using cardiac-gated CT. This is because CAC has a high density and is sensitive to motion artefacts leading to false CAC values (27). New technology of multi-detector computed tomography scanners with faster gantry rotation times and thinner detector row widths allow for thinner slices with a reduction in partial volume effects. These changes in hardware now allow for more exact and reliable measurement of CAC on non-gated NCCT scans (NG-NCCT). In a study by Wu et al (28) on 483 patients showed excellent correlation of Agatston CAC scores between a dedicated cardiac gated non-contrast CT for calcium scoring (16 slice multidetector, 3.0 mm slice thickness) and a low dose NG-NCCT (16 slice multidetector, 0.75mm slice thickness )performed for lung cancer screening (Figure 1). In their cohort of NG-NCCT patients the average heart was 61 beats per minute. They did not assess the importance of potential heart rate dependent motion artifact that may limit the accurate quantification of calcium score using non gated CT protocols.(28) They found an intraclass correlation coefficient of 0.95 for the agreement between the scores on low-dose NG-NCCT versus the respective routine cardiac-gated CT for CAC in this one observer study. In a study by Kim et al., where 128 patients underwent both non-gated low dose lung cancer screening and ECG-gated CAC scanning, an accuracy of 90% was observed for CAC>0 on the gated CAC scan and the absolute CAC scores correlated well (r=0.89) (29). In a meta-analysis of 661 subjects (3 separate studies) performed in 2013, Xie et al convincingly showed that, when the Agatston Score at non-gated low dose NCCT was compared with the gold standard of routine cardiac gated CT performed for CAC scoring, the pooled correlation coefficient was 0.94 (95%CI: 0.89-0.96). These data are confirmative of the newly available scatter plot from Wu et al(28) (Figure 1) showing a R^2 of 0.95 between Agatston scores as derived from NG-NCCT versus cardiac gated CT.
While the Agatston score as a continuous measurement has been established for formal CAC assessment, the development of visual scores for CAC categorization is essential in order to provide the chest radiologist with a simple technique that is less time consuming. Several studies have been performed showing that either a visual-qualitative assessment or a visual ordinal scale can be used for reliable and accurate risk assessment as compared to Agatston score (30-32). But more importantly, both Agatston score and/or a visual CAC assessment from NG-NCCT have prognostic value for cardiovascular events and overall mortality. In detail, a study performed by Mets et al in 3,648 lung cancer screening patients using an automatically derived Agatston score from NG-NCCT in a risk prediction model found overall good discrimination (AUC 0.71) with an event frequency of 12.2% vs 4.0% in the high vs. low risk groups, respectively. (33) In the ECLIPSE trial Williams et al found that CAC was increased in patients with chronic obstructive pulmonary disease and was associated with an increased risk of death. (34) In the National Lung Screening Trial assessing 1,442 patients (35), an Agatston scores of 1-100, 101-1000, and >1000 had HR of 1.27, 3.57, and 6.63 as derived from NG-NCCT and compared to an Agatston score of 0. Interestingly, in a case-control study authored by Hughes-Austin et al. in which both ECG-gated 3 mm and non-gated 6 mm CT scans were available, the predictive value of the Agatston score for mortality where similar. (36) Focusing on visual assessment, Shao et al showed in a single centre study that there is no significant difference in the discriminative power of visual CAC assessment vs. Agatston score (AUC: 0.80, 0.81). (37) Most evidence exist for a visual assessment using an ordinal CAC scoring system categorizing from 0-12 or 0-30 based upon visual estimation (Table 1). The study of Shemesh et al. including 8,782 smokers with 72 months mean follow up showed that this simple ordinal system was strongly predictive for cardiovascular death (32) and further confirmed by Blair et al. to be of similar predictive value as the Agatston score (31) (Table 2). Gonzales et al have recently shown that automated detection of Agatston scores can be derived from NG-NCCT exams. (38) Thus, in a common guideline, the Society of Cardiovascular Computed Tomography (SCCT) and the Society of Thoracic Radiology (STR) recommend “the incorporation of CAC into all non-gated non-contrast chest examination reports” since it “in the treatment of coronary artery disease”.(39)

It is very clear that coronary artery calcium can be reliably detected on NG-NCCT and that either ordinal scoring methods or quantification of the NG-NCCT Agatston score are highly correlated (within 10%) with those cardiac gated non-contrast CT exams that are performed only for CAC scoring. **An argument can be made that the**
CAC score value obtained using current state of the art multidetector NG- NCCT of the chest, performed for any reason, are a good proxy for a dedicated CAC scoring CT.

Aortic calcification

The thoracic aorta is another important vascular bed imaged on a standard chest CT. As compared to the coronary arteries, the assessment thoracic aorta calcification (TAC) less standardized but also less effected by cardiac motion. In a retrospective study by Jairam et al. found good predictive value for cardiovascular events when including visual assessment of TAC (HR: 0.37, p<0.001) into a larger predicting model. Similar results were observed in the Heinz Nixdorf RECALL study, where TAC together with other CT-derived parameters improved the prediction of events over the Framingham Risk Score and CAC (AUC: 0.749 to 0.764; p=0.01). In contrast, Kim et al found in subjects from the MESA study without CAC (n=3,415) that TAC was associated to cardiovascular events and all-cause mortality, but this association attenuated after adjustment for cardiovascular risk factors. Similarly, in the Framingham Heart Study TAC provided no incremental value above risk factors for the prediction of events. Thus, TAC is a prognostic marker, but its incremental value to traditional risk factors and other CT-findings, particular to CAC remain controversial.

Valvular Calcification

The most common valve affected by calcification is the aortic valve. The aortic valve calcification (AVC) can vary by its degree and/or by its location and can lead to aortic stenosis. The degree of stenosis is increasing with AVC extent, while calcification of the peripheral left-posterior and the central right-left commissural leaflets is particularly correlated with mean and peak gradient increases across the aortic valve. The underlying pathophysiology is complex and integrates lipids, the renin-angiotensin system, inflammation, signalling pathways, and genetic predisposition. Also, a strong linkage to visceral obesity has been described leading the neologism ‘valvulo-metabolic’ risk. Further, AVC shares common risk factors with arteriosclerosis; hence, patients with AVC had more frequently coexisting presence of coronary plaque and had a greater extent of coronary plaque burden (6.4 vs 1.8 segments for patients with and without AVC, P<0.001) as described in a study of 357 subjects undergoing cardiac
Interestingly, AVC was more strongly associated with calcified (OR: 5.2, p=0.004), then with mixed (OR: 3.2, p=0.02) or non-calcified plaque (P=0.96). Several studies have been performed regarding the prognostic value of AVC for cardiovascular events and all-cause mortality. Although AVC showed a prognostic value in univariate analysis, it attenuated in most studies after adjustment for traditional risk factors and after further adjustment for CAC and/or TAC.(43, 48-50)

**Annular Calcification**

The annulus of the mitral valve is most commonly calcified. Mitral annular calcification (MAC) is a chronic degenerative process in the fibrous base of the mitral valve and more commonly affects the posterior annulus than the anterior annulus. (51) Traditionally, MAC is assessed using echocardiography and several studies using this technology showed independent association of MAC with cardiac events.(52, 53) Given a good relationship in MAC between echocardiography and CT (54), MAC was also a good predictor for cardiovascular events if assessed by CT (55, 56). In the Northern Manhattan Study (n=1,955) (55), MAC prevalence was 27%, while severe MAC (>4mm thickness) was observed in 13%. Presence of MAC was associated with myocardial infarction (HR: 1.75) and cardiac death (HR: 1.53) and these associations became stronger if using severe MAC as the predictor (HR: 1.89 and 1.81; respectively). In this cohort, but also in a cohort with atrial fibrillation, MAC was not significantly associated with cerebrovascular events. (55, 56)

Caseous calcification of the mitral valve is a rare form of MAC. The contents of the hollowed out cavity in the mitral valve annulus is composed of a mixture of calcium, fatty acids, and cholesterol that has a “toothpaste-like” texture. This commonly presents as an intracardiac mass at echocardiography. There is limited evidence regarding the prognostic value of caseous calcification of the mitral annulus. In a literature review of 1,502 articles, Dietl et al. identified a total of 130 patients with caseous calcification of the mitral annulus reported in 86 publications. The prevalence of cerebrovascular events was higher in patients with caseous calcification of the mitral annulus than with simple MAC (19% vs 12%, respectively; p=0.02).

**Atrial and Ventricular size**
There is a large body of evidence that MetS carries an increased risk of left ventricle (LV) hypertrophy, left atrial (LA) enlargement, systolic and/or diastolic dysfunction, arrhythmias and interstitial myocardial fibrosis. MetS is also associated with increased LV mass and LV diastolic dysfunction.\(^{(57, 58)}\) CT can be useful for assessing cardiac chambers to determine their size, shape and thickness. Cardiac gated CT scans can usually be obtained during diastole for CAC scoring and coronary angiography, as this phase of the cardiac cycle has the least motion. While chamber assessment is relatively simple for gated, contrast-enhanced CT scans given existing software tools, NG-NCCT exams are more challenging and an area-based approach has been proposed. Schlett et al. showed that an area-based measurement for LV on axial, non-contrast enhanced CT images correlates well with LV volume, mass and size (r=0.68; r=0.73; r=0.82).\(^{(59)}\) Similar correlations were observed for the left atrium.\(^{(60)}\) In the MESA cohort, such area-based LV measurement of non-contrast CT scans is a predictor of incident heart failure events (HR 1.15; 95%CI 1.11-1.20) beyond traditional risk factors and CAC score; but also for CHD events (HR 1.07; 95%CI 1.03-1.10).

As RV and LV contraction is usually synchronous, the RV/LV diameter and volume ratios have been used in NG-NCCT studies to assess RV dilation and dysfunction in response to increased RV afterload. (Henzler et al 2012, Mansencal et al. 2005) A limited number of reports indicate that RV hypertrophy may parallel alterations in LV structure and function in the setting of systemic hypertension, obesity and diabetes. (Chahal et al 2012) All the components of MetS (increased blood pressure, abdominal obesity, increased fasting glucose level and dyslipidemia) may induce right ventricular remodelling by several hemodynamic and non-hemodynamic mechanisms. (Tadic et al. 2013) Increasing evidence suggests that in pulmonary hypertension (PH) RV dysfunction is associated with various components of MetS, such as insulin resistance, hyperglycemia, and dyslipidemia. (Talati et al. 2015)

Regarding LA assessment, an enlarged size was associated with a 3- to 5-fold increase risk for ACS and provided incremental value for predicting ACS when added to the CT finding of indeterminate coronary artery stenosis in a population with acute chest pain presenting to the ED. (61) In the Heinz-Nixdorf Recall Study (62), LA size had prognostic value (HR 1.48), which remained significant after adjustment for traditional risk factors (HR 95%CI: 1.09-1.43) and after adjustment for traditional risk factors plus CAC (HR 95%CI: 1.07-1.40) \((\text{Table 2})\). Prognostic value of LA size was similar for different endpoints (coronary event: HR: 1.21; stroke: 1.31; CV death: 1.33). LA size also remained associated with cardiovascular events independent of other CT non-coronary
findings. Recently Jivraj et al have shown in 165 patients with right heart catheterization proven pulmonary hypertension (PAP > 45 mm Hg) and capillary wedge pressures (43 patients - PCWP > 15 mm Hg, 122 patients PCWP < 15 mm Hg) that left atrial maximal cross-sectional area (LA-MACSA) measured from NG-NCCT (LA-MACSA > 2400mm², \( P < 0.001 \)) had a 44% sensitivity and 93% specificity for pulmonary hypertension from left heart disease. (63) On NG-NCCT studies the images may not reveal the true ventricular morphology because the phase of the cardiac cycle is unknown. However, a few studies have reported good sensitivity and specificity (both >68%) of standard axial, non-gated chest CT for cardiomyopathies. (64)

**Left ventricle**

The left ventricle size (volume and in-plane area) can be estimated from NCCT chest exams. Bhatt and colleagues (65) have created an automated process for generating the expected ventricular sizes from NG-NCCT chest exams by comparing these studies to ultrasound and cardiovascular MRI exams that show the ventricular volumes and wall thickness (Supplemental Figure 1). The assessment of ventricular volume and wall thickness is easier if the patient is anemic, as the ventricular chambers are seen to be of lower Hounsfield unit density than the walls. The presence of prior left ventricular myocardial infarction is also easily determined by the presence of a low density scar (Figure 3). These are typically seen in the subendocardial regions of the wall and may be transmural.

Recently Kockelkoren et al published their data from routine NG-NCCT exams on patients that were studied for non-cardiovascular disease (Tables 3 and 4). This was derived from a rather homogeneous population of Caucasians in the United Kingdom. This group of researchers created a simple to use ordinal grading scale for the determination of future major adverse cardiac events (MACE) (Table 3) and have a computational model for the likelihood of a major cardiac event within 5 years that is based on a best fit multivariable regression model (Supplementary Tables S2, S3). The parameters include: age, male gender, indication for exam, left anterior descending coronary artery calcium (LAD Ca++) value, mitral valve leaflet calcification (MV CA++) value, descending aorta calcium value (DSC Ca++), and the maximum transverse diameter (cm) of the heart.

**Epicardial Fat**
In their study of 3,630 subjects from the Heinz-Nixdorf Recall Study, Mahabadi et al (41) found that the epicardial fat volume (HR: 1.15, 95% C.I 1.01-1.30, p value 0.03), was an imaging biomarker predictive of myocardial infarction, stroke and cardiovascular death (Table 5). In their systematic review, Bertaso et al found that the heterogeneity of the studies limits the conclusions that can be drawn from using this metric. They found that this visceral fat deposit is highly correlated with obesity, diabetes mellitus, age and hypertension. Manno et al showed that epicardial fat thickness at ultrasound was correlated with higher LDL cholesterol. (66) In their study from 2018, Hedgire et al show that perivascular fat stranding, seen on coronary CT angiography is associated with high risk clinical features and they suggest that fat stranding is a potential imaging biomarker of high-risk and/or ruptured atherosclerotic plaques. (67) Hartiala et al found no evidence that increased epicardial fat volume was independently associated with pre-clinical atherosclerosis. (68) Instead, they found that epicardial fat volume was primarily associated with BMI and waist circumference. (68) Furthermore, there is increasing evidence that fat quality rather than volume may play a role in the association to CVD. (69)

**Pulmonary artery diameter predicts pulmonary hypertension**

Sleep disordered breathing (sleep apnea) is an important cause of pulmonary hypertension. (70) Obstructive Sleep Apnea (OSA) is caused by the increased collapsibility of the upper airway from loss of muscle tone and a decrease in the effective orifice from fat deposition in the tongue and surrounding pharynx during sleep. (71) This results in decreased or absent airflow and hypoxia. These episodes are usually terminated by a brief arousal from sleep and resulting in sleep deprivation for subjects with MetS. (72) Over many years, these apneic episodes lead to sleep fragmentation and altered cognitive function. (73) These episodes of hypoxia are associated with pulmonary artery vasoconstriction and can lead to permanent changes in PA size (Figure 5). (74) Corson et al studied 175 subjects with right heart catheterization (RHC) proven pulmonary hypertension (PH), 16 normal patients with proven normal mean pulmonary artery pressures (mPAP) and 114 subjects without known mPAP and found a sensitivity of the criterion “mean pulmonary artery diameter at the level of the bifurcation >29mm” was 0.89 (95% C.I. 0.84-0.93) and a specificity of 0.83 (95% CI: 0.76-0.90). (75) Truong et al studied 706 “healthy cohort” subjects in the Framingham Heart Study using cardiac gated NCCT and found a 90th percentile cut-off value of 28.9 mm in men and 26.9 mm in women. (76) Pulmonary artery diameter is an important clue that may indicate pulmonary
hypertension from any cause (77); in the setting of obesity or MetS an enlarged PA can be used to alert the imager and clinician to the possibility for OSA. Instituting treatment with Continuous Positive Airway Pressure (CPAP) can significantly improve the length and quality of life for these individuals.

Radiation dose and safety using NG-NCCT for the diagnosis of MetS

We are not proposing to use NCCT for the diagnosis of MetS or obesity. From studies performed for other indications, the imaging physician can also make inferences about the metabolic milieu of that subject based on the multiple imaging findings discussed in this review. For the most part low dose chest CT protocols are very low contributors to the medical radiation any patient receives over the course of their lifetime.(78) Each scan delivers between 0.5 and 5 mSv depending on the patient size, use of dose lowering reconstruction methods and automatic exposure control (limit mAs).(79)

Conclusion

The beauty of non-gated, non-contrast computed of the chest is that quantitative assessment of Hounsfield unit density, contour and volume of many organs can be assessed longitudinally and correlated to patient outcomes. This differs substantially from contrast enhanced CT data, because there is no iodinated contrast material confounding the density measurements. There are easy to access imaging biomarkers associated with obesity, atherosclerotic disease and MetS that are routinely seen on these exams. The most important one found on NG-NCCT is coronary artery calcification. Various models combining clinical and imaging data have been shown to have prognostic significance for Major Adverse Cardiac Events. Thus, these exams are a virtual treasure trove of quantitative imaging biomarker information available for retrospective analysis to create survival models (training sets) that can be applied prospectively to test sets and validated with external data sets. These big data can be added to radiomic feature analysis, convolutional neural networks and/or added to deep neural networks without any user defined features to create better survival models that can be used to help design personalized medical interventions aimed at prolonging quality life expectancy.
References


80. Shemesh J. Coronary artery calcification in clinical practice: what we have learned and why should it routinely be reported on chest CT? Ann Transl Med. 2016;4(8):159.

Legends

Legend Figure 1: Data from Wu et al (28) in a study comparing Agatston Calcium Scores on non-cardiac gated, non-contrast low dose CT (LDCT) performed for lung cancer screening to standard cardiac gated, non-contrast computed tomography (NCCT) in 513 consecutive cases. This shows excellent correlation between these two ways to quantify Agatston coronary artery calcification scores ($R^2=0.95$). They found a systematic under quantification of CAC using LDCT ($y$ intercept $= -12.1$). Thus, any coronary artery calcification found at LDCT is worthy of quantification. This can be performed either by ordinal scoring or using post processing to obtain the non-cardiac gated LDCT Agatston score. (Scatter plot of the raw data made expressly for this article by Ming-Ting Wu, M.D.)

Legend Figure 2: Non gated, non-contrast computed tomography of the chest with globular calcification of an atherosclerotic plaque at the origin of the left anterior descending coronary artery (arrow head).

Legend Figure 3: Non-gated, non-contrast computed tomography of the chest coned down to the heart (A) axial and (B) short axis reconstruction showing a fibrofatty subendocardial scar (arrows) in the left ventricular septum, inferior and inferolateral walls from an old myocardial infarction in the right coronary artery vascular territory. Note the presence of hepatic steatosis as well (A) with a liver density of 35 Hounsfield units (ROI - Region of interest).

Legend Figure 4: 45 year old Caucasian male with (A) borderline evidence for low iodine organification in the thyroid with a thyroid density of 64 (Normal range 80-120 HU) (B) non gated Agatston score of 2 is at least in the 79th percentile for age and sex. There was hepatic steatosis as well (C) with a liver density of 42.9 HU. The
Paraspinous muscle density was low measuring 33.8 HU at the T12 level (Normal range 5-60HU, from unpublished data (Tsuchiya et al, submitted)). This constellation of findings is the imaging equivalent of the clinically defined Metabolic Syndrome and suggests both glucose intolerance and an increase in overall inflammatory cytokines due to the low paraspinous muscle density.

**Legend Figure 5:** Pulmonary trunk measured at the largest part of the right main pulmonary artery is 4.0 cm (white line). This is abnormal and is suggestive of the possibility of pulmonary hypertension/pulmonary arterial hypertension. In an obese individual a common cause is sleep disordered breathing (sleep apnea) which can be treated with a night time Continuous Positive Airway Pressure (CPAP) mask.

Legend Supplemental Figure 1: Automatic segmentation of the left and right ventricular cavities from non contrast non cardiac gated chest CT exams using the method of Bhatt et al (65), (A) axial chest CT with the estimated left ventricle cavity in light red and the estimated left ventricular wall in dark red, with the estimated right ventricle in blue, (B) sagittal non contrast CT showing the estimated left ventricle in red and the estimated right ventricle in blue. (C) coronal chest CT showing the estimated left ventricle in red and the estimated right ventricle in blue, (D) Entire volume of left ventricle in red and right ventricle in blue.

**Legend Table 1:** Importance of coronary artery calcification found on non-cardiac gated chest computed tomography in patients that smoke cigarettes (table modified from Shemesh et al (80)) Practical comments for chest radiologists showing that the larger ordinal coronary artery calcium score is associated with an increased risk of Major Adverse Cardiac Events. (This table is modified from Shemesh et al (80)) Abbreviations: CAC- coronary artery calcium score; Visual Score (Likert Scale range from 0-12); CAD- coronary artery disease, PVD- peripheral vascular disease;

**Legend Table 2:** Imaging findings on non-contrast, non-cardiac gated Chest Computed tomography exams that are reflective of individual biology and the metabolic syndrome. (Abbreviations: n- number affected. N=total in study)

**Legend Table 3:** Imaging based cardiovascular risk biomarkers derived from a Caucasian population in Scotland (N=2124) (81). This type of analytic approach to documenting vascular calcifications was first used by Jairam et al in 2014 (40).

**Legend Table 4:** Hazard Ratios for the most significant model parameters for determining cardiovascular risk from contrast enhanced, non-gated chest CT exams from the PROVIDI study (N=10,410) (40).

**Legend Table 5:** Multivariable analysis of clinical and imaging based cardiovascular risk biomarkers derived from 3,630 subjects enrolled in the prospectively acquired Hienz-Nixdorff Recall Study. (41) and their adjusted Hazard Ratios for the interval development of major adverse cardiac events (MACE). (Abbreviations: FR- Framingham Risk Score, CAC- Coronary artery Agatston Score,)

**Legend Table S1:** Multi-Ethnic Study of Atherosclerosis (MESA) results from Budoff et al(22) modified from Table 2 in the original publication, showing the ten year event rate of major adverse cardiac events based simply off of the gated CT chest coronary artery Agatston calcium scores. These event rates are not adjusted for any clinical risk factors. These data show the effects of CAC transcend age related changes; in that more CAC is worse than simply being old. The Chinese and Caucasian were less affected by CAC than African-Americans and Hispanics.

**Legend Tables S2 and S3:** Kockelkoren (81) Scottish heart study risk 10 year estimated risk model (Table S2) and the equation used to derive the 5 year risk score (Table S3)
Figure 1: A scatter plot showing the relationship between LDCT Agatston Score and Cardiac Gated NCCT Agatston Score. The equation of the line of best fit is $Y = 1.107x - 12.1$, with $R^2 = 0.95$. Click here to access/download: Figure 1 MetS.tif
<table>
<thead>
<tr>
<th>Agatston Score</th>
<th>Visual Score (0-12)</th>
<th>Prognosis</th>
<th>Recommendation</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>No CAC</td>
<td>0</td>
<td>0</td>
<td>More favorable prognosis for CV events;</td>
<td>The presence of chronic obstructive CAD is very unlikely, life style changes</td>
</tr>
<tr>
<td>Mild CAC</td>
<td>1-100</td>
<td>1-4</td>
<td>Mildly increased risk for CV event</td>
<td>Consider further coronary evaluation and primary preventive treatment according to the patient global risk, life style changes should be more emphasized.</td>
</tr>
<tr>
<td>Moderate CAC</td>
<td>101-400</td>
<td>5-7</td>
<td>Mildly increased risk of CV event</td>
<td>Consider further coronary evaluation and primary preventive treatment according to the patient global risk and clinical manifestations; in patients with Framingham risk intermediate and above (≥10% in 10 years) statin therapy should be considered.</td>
</tr>
<tr>
<td>Severe CAC</td>
<td>&gt;400</td>
<td>8-12</td>
<td>Significantly increases the CV risk and total mortality</td>
<td>In asymptomatic subjects, consider further coronary evaluation by stress ECG, stress echo or SPECT imaging to R/O obstructive CAD; statin therapy should be highly considered.</td>
</tr>
</tbody>
</table>

Table 1: Importance of coronary artery calcification found on non-cardiac gated chest computed tomography in patients that smoke cigarettes (table modified from Shemesh et al) (70) Practical comments for chest radiologists showing that the larger ordinal coronary artery calcium score is associated with an increased risk of Major Adverse Cardiac Events. (This table is modified from Shemesh et al (70)) Abbreviations: CAC- coronary artery calcium score; Visual Score (Likert Scale range from 0-12); CAD- coronary artery disease, PVD- peripheral vascular disease;
<table>
<thead>
<tr>
<th>Non contrast, Chest CT finding</th>
<th>Index cases (n)/ Normal Values (N) [n/N]</th>
<th>Abnormal Value [n/N]</th>
<th>Unadjusted Hazard Ratio For MACE or Death (95% CI)<em>p value</em></th>
<th>Adjusted Hazard Ratio (95% CI)<em>p value</em></th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Heart</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transverse diameter of heart</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Leiner article</td>
</tr>
<tr>
<td>Left Atrial Index, mm²/m²</td>
<td>917 ± 187 [3389/3630]</td>
<td>992 ± 214 [241/3630]</td>
<td>1.42 (1.27-1.59) <em>&lt;0.0001</em></td>
<td>1.18 (1.02-1.37) <em>0.023</em></td>
<td>Gated exam Mahabadi 2016</td>
</tr>
<tr>
<td>Left Ventricular Index, mm²/m²</td>
<td>2,146 ± 275 [3389/3630]</td>
<td>2,240 ± 305 [241/3630]</td>
<td>1.36 (1.21-1.52) <em>&lt;0.0001</em></td>
<td>1.08 (0.93-1.25) <em>0.31</em></td>
<td>Gated exam Mahabadi 2016</td>
</tr>
<tr>
<td>Epicardial Fat Volume, ml</td>
<td>92.7 ± 46.0 [3389/3630]</td>
<td>117.5 ± 55.6 [241/3630]</td>
<td>1.52 (1.38-1.68) <em>&lt;0.0001</em></td>
<td>1.18 (1.02-1.34) <em>0.023</em></td>
<td>Gated exam Mahabadi 2016</td>
</tr>
<tr>
<td>Ascending or Descending Aortic Calcification</td>
<td>Ca++ present 61.5% [2083/3630]</td>
<td>Ca++ present 77.2% [186/241]</td>
<td>2.08 (1.54-2.81) <em>&lt;0.0001</em></td>
<td>1.18 (0.83-1.57) <em>0.41</em></td>
<td>Gated exam Mahabadi 2016</td>
</tr>
<tr>
<td>Aortic Valve Calcifications</td>
<td>Ca++ Present 10.3% [324/3,389]</td>
<td>Ca++ Present 19.9% [48/241]</td>
<td>2.34 (1.7-3.2) <em>0.0001</em></td>
<td>1.03 (0.73-1.44) <em>0.88</em></td>
<td>Gated exam Mahabadi 2016</td>
</tr>
<tr>
<td>Ascending Aortic Diameter at Pul Art bifurcation</td>
<td>35.5 ± 4.0 [3389/3630]</td>
<td>37.1 ± 4.1 [241/3630]</td>
<td>1.44 (1.29-1.61) <em>&lt;0.0001</em></td>
<td>1.02 (0.94-1.06) <em>0.25</em></td>
<td>Gated exam Mahabadi 2016</td>
</tr>
<tr>
<td>Descending Aortic Diameter (mm) at Pul Art bifurcation</td>
<td>26.5 ± 2.9 [3389/3630]</td>
<td>27.9 ± 2.7 [241/3630]</td>
<td>1.56 (1.39-1.76) <em>&lt;0.0001</em></td>
<td>0.94 (0.88-1.03) <em>0.06</em></td>
<td>Gated exam Mahabadi 2016</td>
</tr>
<tr>
<td>Mitral Valve Leaflet Calcium</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Andreas H. Mahnken1,2</td>
</tr>
<tr>
<td>Mitral Valve Annulus Calcium</td>
<td>2.4% [76/3,389]</td>
<td>4.2% [10/241]</td>
<td>1.9 (1.01-3.58) <em>0.0001</em></td>
<td>0.73 (0.38-1.40) <em>0.34</em></td>
<td>Gated exam Mahabadi 2016</td>
</tr>
</tbody>
</table>

Legend Table 2: Imaging findings on non-contrast, non-cardiac gated Chest Computed tomography exams that are reflective of individual biology and the metabolic syndrome. (Abbreviations: n-number affected. N=total in study)
<table>
<thead>
<tr>
<th>NCCT imaging Finding</th>
<th>Absent Score=0</th>
<th>Mild Score=1</th>
<th>Moderate Score=2</th>
<th>Severe Score=3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left anterior descending coronary artery calcification</td>
<td>none</td>
<td>1 or 2 calcified plaques limited to 2 or fewer images</td>
<td>Greater than 2 focal plaques or calcification extending for more than 2 slices</td>
<td>Fully calcified coronary artery extending for more than 3 slices</td>
</tr>
<tr>
<td>Descending Thoracic Aorta Calcification</td>
<td>none</td>
<td>Less than or equal to 3 focal calcified plaques</td>
<td>4-5 focal calcified plaques or one plaque extending for 3 or more slices</td>
<td>More than 5 focal calcified plaques or 2 plaques extending beyond 3 slices</td>
</tr>
<tr>
<td>Mitral valve leaflet Calcification</td>
<td>none</td>
<td>One leaflet calcified</td>
<td>Two leaflets calcified</td>
<td></td>
</tr>
</tbody>
</table>

Legend Table 3: Imaging based cardiovascular risk biomarkers derived from a Caucasian population in Scotland (N=2124) (71). This type of analytic approach to documenting vascular calcifications was first used by Jairam et al in 2014 (36).
Table 4

<table>
<thead>
<tr>
<th>Model feature</th>
<th>Hazard Ratio</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>1.41</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Descending Aorta Calcification</td>
<td>1.45</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mitral Valve Calcification</td>
<td>1.25</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LAD Calcification</td>
<td>1.11</td>
<td>&lt;0.003</td>
</tr>
<tr>
<td>(Maximum Transverse Cardiovascular diameter in cm - 11 cm$^2$)</td>
<td>1.03</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age</td>
<td>1.03</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Legend Table 4: Hazard Ratios for the most significant model parameters for determining cardiovascular risk from contrast enhanced, non-gated chest CT exams from the PROVIDI study (N=10,410) (36).
<table>
<thead>
<tr>
<th>Model feature</th>
<th>Hazard Ratio Adjusted for FR score, CAC score and Multiple CT measures (95% C.I.)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left atrial index</td>
<td>1.21 (1.07-1.36)</td>
<td>0.002</td>
</tr>
<tr>
<td>Left ventricular index</td>
<td>1.15 (1.02-1.29)</td>
<td>0.02</td>
</tr>
<tr>
<td>Epicardial Fat Volume</td>
<td>1.14 (1.01-1.28)</td>
<td>0.04</td>
</tr>
<tr>
<td>Presence of Thoracic Aortic Calcification</td>
<td>1.14 (0.83-1.56)</td>
<td>0.43</td>
</tr>
<tr>
<td>Diameter of Ascending aorta</td>
<td>0.98 (0.84-1.15)</td>
<td>0.25</td>
</tr>
<tr>
<td>Aortic Valve Calcification</td>
<td>1.01 (0.72-1.40)</td>
<td>0.98</td>
</tr>
<tr>
<td>Diameter of the Descending thoracic Aorta</td>
<td>0.98 (0.84-1.15)</td>
<td>0.84</td>
</tr>
<tr>
<td>Mitral Annulus Calcification</td>
<td>0.81 (0.43-1.54)</td>
<td>0.81</td>
</tr>
</tbody>
</table>

Legend Table 5: Multivariable analysis of clinical and imaging based cardiovascular risk biomarkers derived from 3,630 subjects enrolled in the prospectively acquired Hienz-Nixdorff Recall Study. (37) and their adjusted Hazard Ratios for the interval development of major adverse cardiac events (MACE). (Abbreviations: FR- Framingham Risk Score, CAC- Coronary artery Agatston Score,)
Click here to access/download
Supplemental Data File (.doc, .tif, pdf, etc.)
Table S1.docx
Table S2

Click here to access/download
Supplemental Data File (.doc, .tif, pdf, etc.)
Supplementary Table S2.docx
Click here to access/download
Supplemental Data File (.doc, .tif, pdf, etc.)
Supplementary Table S3.docx
Supplemental Data File (.doc, .tif, pdf, etc.)
Table S1 S2 and S3.docx